UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing

0001811884-23-000013.txt : 20230505 0001811884-23-000013.hdr.sgml : 20230505 20230505122205 ACCESSION NUMBER: 0001811884-23-000013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 23892363 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 10-Q 1 utmd-20230331.htm UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-12575

UTAH MEDICAL PRODUCTS INC

(Exact name of Registrant as specified in its charter)

Utah	87-0342734
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

7043 South 300 West

Midvale, Utah 84047

(Address of principal executive offices) (Zip Code)

(801) 566-1200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol:	Name of each exchange on which registered:
Common stock, $0.01 par value	UTMD	NASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of May 4, 2023: 3,628,067.

Table of Contents

UTAH MEDICAL PRODUCTS, INC.

INDEX TO FORM 10-Q

		PAGE
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements

	Consolidated Condensed Balance Sheets as of March 31, 2023 and December 31, 2022	1

	Consolidated Condensed Statements of Income for the three months ended March 31, 2023 and March 31, 2022	2

	Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2023 and March 31, 2022	3

	Consolidated Condensed Statements of Stockholders’ Equity for the three months ended March 31, 2023 and March 31, 2022	4

	Notes to Consolidated Condensed Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	7

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14

Item 4.	Controls and Procedures	14

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	15

Item 1A.	Risk Factors	15

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	16

Item 6.	Exhibits	16

SIGNATURES		17

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
MARCH 31, 2023 AND DECEMBER 31, 2022
(in thousands)
	(unaudited)	(audited)
	MARCH 31, 2023	DECEMBER 31, 2022
ASSETS
Current assets:
Cash & Investments	$ 80,912	$ 75,052
Accounts & other receivables, net	3,818	5,538
Inventories	9,940	8,814
Other current assets	442	515
Total current assets	95,112	89,919
Property and equipment, net	10,241	10,224
Goodwill	13,502	13,354
Other intangible assets	53,443	52,755
Other intangible assets - accumulated amortization	(44,528)	(42,378)
Other intangible assets, net	8,915	10,377
Total assets	$ 127,770	$ 123,874

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$ 1,028	$ 1,218
Accrued expenses	5,046	4,742
Total current liabilities	6,074	5,960
Deferred tax liability – Femcare IIA	1,456	1,514
Other long term liabilities	1,256	1,256
Long-term lease liability	328	341
Deferred income taxes	638	549
Total liabilities	9,752	9,620

Stockholders' equity:
Common stock - $0.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares	36	36
Accumulated other comprehensive loss	(11,490)	(12,039)
Additional paid-in capital	322	251
Retained earnings	129,150	126,006
Total stockholders' equity	118,018	114,254

Total liabilities and stockholders' equity	$ 127,770	$ 123,874

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022
(in thousands, except per share amounts - unaudited)
	THREE MONTHS ENDED MARCH 31,
	2023	2022
Sales, net	$ 12,520	$ 12,323

Cost of goods sold	4,677	4,790
Gross profit	7,843	7,533

Operating expense
Selling, general and administrative	3,260	2,888
Research & development	144	123
Total operating expenses	3,404	3,011
Operating income	4,439	4,522

Other income	680	8
Income before provision for income taxes	5,119	4,530

Provision for income taxes	905	996
Net income	$ 4,214	$ 3,534

Earnings per common share (basic)	$ 1.16	$ 0.97

Earnings per common share (diluted)	$ 1.16	$ 0.96

Shares outstanding (basic)	3,628	3,655

Shares outstanding (diluted)	3,636	3,665

Other comprehensive income (loss):
Foreign currency translation net of taxes of $0 in all periods	$ 549	$ (506)
Total comprehensive income	$ 4,763	$ 3,028

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022
(in thousands - unaudited)
	THREE MONTHS ENDED MARCH 31,
	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 4,214	$ 3,534
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	155	149
Amortization	1,596	1,646
Provision for losses on accounts receivable	1	8
Amortization of right-of-use assets	13	14
Deferred income taxes	(3)	(144)
Stock-based compensation expense	50	43
Tax benefit attributable to exercise of stock options	2	-
Changes in operating assets and liabilities:
Accounts receivable and other receivables	1,789	(578)
Inventories	(1,084)	(809)
Prepaid expenses and other current assets	25	(109)
Accounts payable	(193)	695
Accrued expenses	350	597
Total adjustments	2,701	1,512
Net cash provided by operating activities	6,915	5,046

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment	(43)	(237)
Net cash used in investing activities	(43)	(237)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	21	19
Payment of dividends	(1,070)	-
Net cash provided by/(used in) financing activities	(1,049)	19

Effect of exchange rate changes on cash	37	71
Net increase in cash and cash equivalents	5,860	4,899
Cash at beginning of period	75,052	60,974
Cash at end of period	$ 80,912	$ 65,873

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for income taxes	$ 129	$ 82
Cash paid during the period for interest	-	-

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY FOR THE
THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022
(in thousands - unaudited)
				Accumulated
			Additional	Other		Total
	Common Stock		Paid-in	Comprehensive	Retained	Stockholders'
	Shares	Amount	Capital	Income	Earnings	Equity
Balance at December 31, 2022	3,628	$ 36	$ 251	$ (12,039)	$ 126,006	$ 114,254
Shares issued upon exercise of employee stock options for cash	-	-	21	-	-	21
Stock option compensation expense	-	-	50	-	-	50
Foreign currency translation adjustment	-	-	-	549	-	549
Common stock dividends	-	-	-	-	(1,070)	(1,070)
Net income	-	-	-	-	4,214	4,214
Balance at March 31, 2023	3,628	$ 36	$ 322	$ (11,491)	$ 129,150	$ 118,018

Balance at December 31, 2021	3,655	$ 37	$ 841	$ (9,054)	$ 115,314	$ 107,138
Shares issued upon exercise of employee stock options for cash	-	-	19	-	-	19
Stock option compensation expense	-	-	43	-	-	43
Foreign currency translation adjustment	-	-	-	(506)	-	(506)
Common stock dividends	-	-	-	-	(1,060)	(1,060)
Net income	-	-	-	-	3,534	3,534
Balance at March 31, 2022	3,655	$ 37	$ 903	$ (9,560)	$ 117,788	$ 109,168

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC.

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(unaudited)

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards.

The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

(3) Inventories at March 31, 2023 and December 31, 2022 consisted of the following:

		March 31, 2023		December 31, 2022
Finished goods	$	1,935	$	1,896
Work-in-process		1,500		1,193
Raw materials		6,505		5,725
Total	$	9,940	$	8,814

(4) Stock-Based Compensation. At March 31, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended March 31, 2023 and 2022, the Company recognized $50 and $43, respectively, in stock based compensation cost.

(5) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022 or March 31, 2023.

(6) 1Q 2023 global revenues (USD) by product category:

		Domestic		Outside US		Total
Obstetrics	$	806	$	209	$	1,015
Gynecology/Electrosurgery/Urology		2,520		3,073		5,593
Neonatal		1,385		377		1,762
Blood Pressure Monitoring and Accessories		2,474		1,676		4,150
Total	$	7,185	$	5,335	$	12,520

Table of Contents

(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie® Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represents an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over the 7 month remaining life, as of the end of 1Q 2023, of the prior CSI agreement with Femcare.

(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2023.

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:

(in thousands)	Three months ended
	March 31,
	2023	2022
Numerator
Net income	4,214	3,534

Denominator
Weighted average shares, basic	3,628	3,655
Dilutive effect of stock options	8	10
Diluted shares	3,636	3,665

Earnings per share, basic	$ 1.16	$ 0.97
Earnings per share, diluted	$ 1.16	$ 0.96

(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General

Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. The Company’s Form 10-K Annual Report for the year ended December 31, 2022 provided a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Analysis of Results of Operations

a)Overview

Income statement results in the first quarter (1Q) of 2023 compared to 1Q 2022 were as follows:

	1Q 2023	1Q 2022	change
Net Sales	$ 12,520	$ 12,323	+1.6%
Gross Profit	7,843	7,532	+4.1%
Operating Income	4,439	4,522	(1.9%)
Income Before Tax	5,119	4,530	+13.0%
Net Income	4,214	3,534	+19.2%
Earnings per Share (diluted)	$ 1.159	$ 0.964	+20.2%

Profit margins in 1Q 2023 compared to 1Q 2022 follow:

	1Q 2023 (JAN – MAR)	1Q 2022 (JAN – MAR)
Gross Profit Margin (Gross Profit/ sales):	62.6%	61.1%
Operating Income Margin (Operating Income/ sales):	35.5%	36.7%
EBT Margin (Profits before Income Taxes/ sales):	40.9%	36.8%
Net Income Margin (Profit after Taxes/ sales):	33.7%	28.7%

Domestic sales in 1Q 2023 were 10% lower, but sales outside the U.S. (OUS) were up 23% in USD terms compared to 1Q 2022. Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in “constant currency” terms, OUS sales were up 28%. Because 28% of consolidated USD sales were invoiced in foreign currencies, the change in FX rates for OUS sales did have an impact on period-to-period relative financial results. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2023 and 1Q 2022 follow:

	1Q 2023	1Q 2022	Change
GBP	1.215	1.339	(9.3%)
EUR	1.078	1.126	(4.2%)
AUD	0.685	0.724	(5.3%)
CAD	0.739	0.789	(6.3%)

The weighted-average negative impact on foreign currency sales was 5.9%, reducing reported USD sales by $223 relative to the same foreign currency sales in 1Q 2022. In constant currency terms, total consolidated 1Q 2023 sales were up $420 (+3.4%).

Due mostly to better absorption of manufacturing overhead costs in Ireland and lower employee healthcare plan costs in the U.S., UTMD was able to increase its 1Q 2023 Gross Profit Margin (GPM), gross profits/sales, compared to 1Q 2022.

Consolidated OI in 1Q 2023 at $4,439 (35.5% of sales) was $84 lower than 1Q 2022 OI of $4,522 (36.7% of sales). Although UTMD’s 1Q 2023 Operating Income Margin (OIM) benefitted from higher sales, a higher GPM and a stronger USD which reduced OUS operating expenses in USD terms by $80, it suffered more from the $348 (2.8% of sales) higher litigation expenses compared to 1Q 2022. The $1,105 per quarter straight-line amortization of the $21,000 purchase price that UTMD paid CSI in early 2019 to acquire the remaining 4.75 years’ exclusive U.S. Filshie distribution rights was 8.8% of 1Q 2023 sales compared to 9.0% of 1Q 2022 sales. The purchase price of CSI’s remaining exclusive distribution rights was recognized as an identifiable intangible asset (IIA) which will be fully amortized in October 2023. IIA amortization expense in total, including that remaining from the 2011 Femcare acquisition, which comprises a significant portion of General & Administrative (G&A) operating expenses, was 12.7% of 1Q 2023 consolidated sales compared to 13.3% of 1Q 2022 consolidated sales. In other words, UTMD’s OIM excluding IIA amortization and litigation expense was 51.4% in 1Q 2023 compared to 50.5% in 1Q 2022.

Income Before Tax (EBT) benefitted from much higher interest income on UTMD’s cash reserves. Non-operating income (NOI) in 1Q 2023, in which interest income is captured, was $681 compared to $8 in 1Q 2022. As a result of $589 higher EBT and a lower income tax provision rate due to a portion of NOI received from tax exempt interest, UTMD’s Net Income Margin (NIM) in 1Q 2023 at 33.7% was substantially higher than the 28.7% NIM in 1Q 2022. UTMD’s consolidated income tax provision rate in 1Q 2023 was 17.7% of EBT compared to 22.0% in 1Q 2022. The result was that 1Q 2023 NI was 19.2% higher, and 1Q 2023 Earnings Per Share were 20.2% higher, than in 1Q 2022.

UTMD’s March 31, 2023 Balance Sheet, in the absence of debt, remained strong. Ending Cash and Investments were $80.9 million on March 31, 2023 compared to $75.1 million on December 31, 2022. Stockholders’ Equity was up $3.8 million in the first three-month calendar period from December 31, 2022. FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2023 and the end of 1Q 2022 follow:

	3-31-23	3-31-22	Change
GBP	1.237	1.315	(6.0%)
EUR	1.087	1.110	(2.0%)
AUD	0.670	0.750	(10.6%)
CAD	0.739	0.801	(7.7%)

Table of Contents

b)Revenues

Terms of sale are established in advance of UTMD’s acceptance of customer orders. In the U.S., Ireland, UK, Canada, Australia and New Zealand, UTMD generally accepted orders directly from and shipped directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD’s Standard Terms and Conditions (T&C) of Sale during both 1Q 2023 and 1Q 2022. UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer’s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD’s disclosure that the selling price is fixed prior to the acceptance of a specific customer order.

Total consolidated 1Q 2023 UTMD revenues (sales) were $197 (+1.6%) higher than in 1Q 2022. Constant currency sales were $420 (+3.4%) higher. U.S. domestic sales were 10.0% lower and OUS sales were 22.9% higher despite an average 5.9% stronger USD. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.

Domestic sales in 1Q 2023 were $7,185 compared to $7,984 in 1Q 2022. The components of domestic sales include 1) “direct sales” of UTMD’s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) “OEM sales” of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) “Filshie device sales”, manufactured by Femcare and distributed in the U.S. by UTMD.

1)Direct sales, representing 50% of total domestic sales, were $372 (9.3%) lower in 1Q 2023 than in 1Q 2022. This was due to continuing supply chain disruption, in particular independent sterilizer capacity constraints.

2)OEM sales, representing 32% of total domestic sales, were $375 (14.0%) lower. U.S. sales to UTMD’s largest OEM customer which had grown rapidly in recent years were $391 lower in 1Q 2023 compared to 1Q 2022.

3)Filshie device sales were $51 (3.9%) lower in 1Q 2023 compared to 1Q 2022.

OUS sales in 1Q 2023 were $5,335 compared to $4,339 in 1Q 2022. OUS sales invoiced in GBP, EUR, AUD and CAD currencies were reduced $223 as a result of changes in FX rates resulting from an average 5.9% stronger USD. In other words, constant currency OUS sales were $5,558, which was 28.1% higher than in 1Q 2022. The foreign currency OUS sales in 1Q 2023 were $3,558, which was 67% of OUS sales and 28% of total consolidated sales. Foreign currency OUS sales in 1Q 2022 were $2,906, which was 67% of OUS sales and 24% of total consolidated sales.

The following table provides USD consolidated sales amounts divided into general product categories for total worldwide sales and the subset of OUS sales:

WW revenues (USD) by product category:

	1Q 2023	%	1Q 2022	%
Obstetrics	$ 1,015	8	$ 1,049	9
Gynecology/ Electrosurgery/ Urology	5,593	45	5,102	41
Neonatal	1,762	14	1,873	15
Blood Pressure Monitoring and Accessories*	4,150	33	4,299	35
Total:	$ 12,520	100	$ 12,323	100

OUS revenues (USD) by product category:

	1Q 2023	%	1Q 2022	%
Obstetrics	$ 209	4	$ 126	3
Gynecology/ Electrosurgery/ Urology	3,073	58	2,522	58
Neonatal	377	7	291	7
Blood Pressure Monitoring and Accessories*	1,676	31	1,400	32
Total:	$ 5,335	100	$ 4,339	100

*includes molded components sold to OEM customers.

Table of Contents

c)Gross Profit

Gross Profit results from subtracting the costs of manufacturing products, including quality assurance and freight for receiving raw materials from vendors, from revenues. UTMD’s Gross Profit was $310 (+4.1%) higher in 1Q 2023 than in 1Q 2022. Gross Profit increased more than revenues due primarily to two favorable period-to-period differences: better absorption of manufacturing overhead costs in Ireland as a result of production which increased more than overhead costs increased, and 2) much lower healthcare costs for U.S. employees compared to 1Q 2022 under UTMD’s self-funded plan. The Company selectively raised product prices during 1Q 2023 based on specific input costs from vendors. As another cost-of-living pay adjustment for employees becomes effective in April 2023, the Company still expects to maintain its GPM for the year as a whole consistent with 2022.

d)Operating Income

Operating Income results from subtracting Operating Expenses from Gross Profit. Operating Expenses are comprised of G&A (G&A) expenses, sales and marketing (S&M) expenses and product development (R&D) expenses. Consolidated Operating Expenses were $3,404 in 1Q 2023 (27.2% of sales) compared to $3,010 in 1Q 2022 (24.4% of sales). Ignoring the portion of Operating Expenses that were litigation expenses and non-cash IIA amortization expenses, consolidated Operating Expenses in 1Q 2023 were 11.2% of consolidated sales compared to 10.6% of sales in 1Q 2022. A stronger USD in 1Q 2023 compared to 1Q 2022 helped Operating Income performance by reducing OUS Operating Expenses in USD terms by $80, comprised of reducing IIA amortization expense by $49 and all other OUS Operating Expenses by $31.

Consolidated G&A expenses were $2,873 (22.9% of sales) in 1Q 2023 compared to $2,551 (20.7% of sales) in 1Q 2022. G&A expenses include litigation costs which were $409 in 1Q 2023 compared to $61 in 1Q 2022. The G&A expenses in 1Q 2023 included $483 (3.9% of sales) of non-cash expense from the amortization of IIA resulting from the 2011 Femcare acquisition, which were $532 (4.3% of sales) in 1Q 2022. The lower USD IIA amortization expense was the result of a stronger USD, as the Femcare amortization expense in GBP in 1Q 2023 was the same as in 1Q 2022. In addition, G&A expenses in both periods included $1,105 IIA amortization expense resulting from the purchase of the CSI remaining U.S. exclusive Filshie distribution rights, which represented 8.8% of 1Q 2023 sales compared to 9.0% of 1Q 2022 sales. Excluding the litigation and non-cash IIA amortization expenses, G&A expenses were $876 (7.0% of sales) in 1Q 2023 compared to $853 (6.9% of sales) in 1Q 2022. The change in FX rates reduced 1Q 2023 OUS G&A expenses by $74, comprised of reducing IIA amortization expense by $49 and all other G&A expenses by $24.

S&M expenses were $387 (3.1% of sales) in 1Q 2023 compared to $336 (2.7% of sales) in 1Q 2022. The change in FX rates reduced 1Q 2023 OUS S&M expenses by $6.

R&D expenses in 1Q 2023 were $144 (1.1% of sales) compared to $123 (1.0% of sales) in 1Q 2022. The change in FX rates reduced 1Q 2023 OUS R&D expenses by $1.

In summary, Operating Income in 1Q 2023 was $4,439 (35.5% of sales) compared to $4,522 (36.7% of sales) in 1Q 2022. The lower Operating Income Margin was due primarily to the $348 higher litigation expenses.

A summary comparison of (USD) consolidated Operating Expenses follows:

	1Q 2023	1Q 2022
S&M Expense	$ 387	$ 336
R&D Expense	144	123
G&A Expense:
CSI IIA amortization	1,105	1,105
Femcare IIA amortization	483	532
Litigation Expense	409	61
All Other G&A Expenses	876	853
Total Operating Expenses:	$ 3,404	$ 3,010

After adjustment of OUS Operating Expenses for a stronger USD, the increases in S&M, R&D and All Other G&A expenses (excluding litigation and IIA amortization) were essentially due to cost-of-living increases for employees.

Table of Contents

e)Non-operating expense/ Non-operating income

Net non-operating expense, or net non-operating income, results from the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income, royalties received from licensing the Company’s technology and other miscellaneous income. Net non-operating income in 1Q 2023 was $681 compared to $8 in 1Q 2022. The primary difference was due to higher average cash balances in 1Q 2023 compared to 1Q 2022 with higher interest rates, which resulted in $646 higher interest income. UTMD also received $9 higher non-operating income in 1Q 2023 from renting underutilized property compared to 1Q 2022, and the same non-operating income from royalties. UTMD realized a slight gain in 1Q 2023 compared to a loss of $3 at the end of 1Q 2022 from remeasurement of foreign currency bank balances.

f)Income Before Income Taxes (EBT)

EBT results from adding net non-operating income to Operating Income. Consolidated 1Q 2023 EBT was $5,119 (40.9% of sales) compared to $4,530 (36.8% of sales) in 1Q 2022. The $589 (+13.0%) higher 1Q 2023 EBT compared to 1Q 2022 was the result of $673 higher non-operating income. In other words, the $646 higher interest income more than offset UTMD’s $348 higher litigation expenses.

The EBT of Utah Medical Products, Inc. in the U.S. was $2,562 in 1Q 2023 compared to $2,916 in 1Q 2022. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,962 in 1Q 2023 compared to EUR 1,806 in 1Q 2022. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP 23 in 1Q 2023 compared to GBP (159) in 1Q 2022. The 1Q 2023 EBT of Utah Medical Products Canada, Inc. was CAD 158 in 1Q 2023 compared to CAD 154 in 1Q 2022.

EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2023 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (“adjusted consolidated EBITDA”) were $6,919 compared to $6,371 in 1Q 2022, an 8.6% increase. Management believes that the 1Q 2023 EBITDA operating performance provides a start that is consistent with achieving its financial objectives for the calendar year 2023, as previously provided in its 2022 SEC 10-K Report. UTMD’s trailing last twelve-month EBITDA was $28,439.

UTMD’s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:

	1Q 2023	1Q 2022
EBT	$ 5,119	$ 4,530
Depreciation Expense	154	149
Femcare IIA Amortization Expense	483	532
CSI IIA Amortization Expense	1,105	1,105
Other Non-Cash Amortization Expense	8	9
Stock Option Compensation Expense	50	43
Interest Expense	-	-
Remeasured Foreign Currency Balances	-	3
UTMD non-US GAAP EBITDA:	$ 6,919	$ 6,371

Table of Contents

g)Net Income

Net Income in 1Q 2023 of $4,214 was 19.2% higher than the Net Income of $3,534 in 1Q 2022. UTMD’s Net Income Margin, Net Income divided by consolidated sales, was 33.7% in 1Q 2023 and 28.7% in 1Q 2022. The average consolidated income tax provision rates (as a % of EBT) in 1Q 2023 was 17.7% and in 1Q 2022 was 22.0%. The lower provision rate in 1Q 2023 resulted primarily from a portion of interest income that is tax-exempt.

h) Earnings Per Share (EPS)

EPS are consolidated Net Income divided by the weighted average number of shares of stock outstanding (diluted to take into consideration stock option awards which are “in the money,” i.e., have exercise prices below the applicable period’s weighted average market value).

Diluted EPS in 1Q 2023 were 20.2% higher than in 1Q 2022. UTMD’s increase in NI was leveraged for EPS as a result of 28,629 fewer diluted shares used to calculate EPS in 1Q 2023 compared to 1Q 2022. Diluted shares were 3,636,286 in 1Q 2023 compared to 3,664,915 in 1Q 2022. Outstanding shares were 3,628,067 at the end of 1Q 2023. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. The total number of outstanding unexercised employee and outside director options at March 31, 2023 was 66,883 at an average exercise price of $73.64, including shares awarded but not yet vested. This compares to 67,433 unexercised option shares at the end of 2022 at an average exercise price of $73.66/ share, including shares awarded but not vested. The difference was due to 300 employee option exercises and 250 cancellations during 1Q 2023. The number of shares added as a dilution factor in 1Q 2023 was 8,456 compared to 10,125 in 1Q 2022.

Outstanding shares at the end of 1Q 2023 were 3,628,067 compared to 3,627,767 at the end of calendar year 2022. The difference was due to 300 employee option exercises during 1Q 2023.

There were no stock repurchases in 1Q 2023. During the last year since the end of 1Q 2022, UTMD repurchased 30,105 of its shares. No options were awarded in 1Q 2023. During the last year since the end of 1Q 2022, 20,600 options were awarded to 40 employees at an exercise price of $82.60.

UTMD paid a $1,070 ($0.295/share) cash dividend to stockholders in 1Q 2023. UTMD did not pay a cash dividend to stockholders in 1Q 2022 because the special $7,309 ($2.00/share) dividend, which was declared in 4Q 2021, was paid in December before the end of the 2021 calendar year instead of in January 2022.

During 1Q 2023 and 1Q 2022, UTMD did not repurchase its shares. In 2Q 2022, UTMD repurchased 30,105 shares at $82.88 per share. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD’s closing share price at the end of 1Q 2023 was $94.77, down 6% from the $100.53 closing price at the end of 2022. The closing share price at the end of 1Q 2022 was $89.86.

i) Return on Equity (ROE)

ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated Stockholders’ Equity for the applicable time period. Annualized ROE (before stockholder dividends) in 1Q 2023 was 15% and in 1Q 2022 was 13%. The higher ROE in 1Q 2023 was due to 19% higher Net Income divided by 7% higher average Stockholders’ Equity. Targeting a high ROE of 20% remains a key financial target for UTMD management. ROE can be increased by increasing Net Income, and/or by reducing Stockholders’ Equity by paying cash dividends to stockholders or by repurchasing shares.

Liquidity and Capital Resources

j)Cash flows

Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $6,915 in 1Q 2023 compared to $5,046 in 1Q 2022. Net Income provided $680 more to cash in 1Q 2023 than in 1Q 2022. Other differences in cash provided during the two periods were a $2,350 higher source of cash from trade accounts receivable, a $141 lower reduction in deferred income taxes and a $135 difference with lower instead of higher prepaid expenses and other current assets, offset by a $886 higher use of cash for accounts payable, a $276 higher increase in inventories and a $247 lower increase in accrued expenses.

Table of Contents

Capital expenditures for property and equipment (PP&E) were $43 in 1Q 2023 compared to $237 in 1Q 2022. Depreciation of PP&E was $155 in 1Q 2023 compared to $149 in 1Q 2022.

Cash dividends paid to stockholders in 1Q 2023 were $1,070 compared to zero in 1Q 2022 because the special $7,309 dividend declared in 4Q 2021 was paid in December 2021 instead of in January 2022.

In 1Q 2023, UTMD received $21 and issued 300 shares of its stock upon the exercise of employee stock options. Option exercises in 1Q 2023 were at an average price of $69.83 per share. In comparison, in 1Q 2022 UTMD received $19 and issued 250 shares of its stock upon the exercise of employee stock options. Option exercises in 1Q 2022 were at an average price of $76.33 per share.

Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to meet the challenges of the current economic environment in achieving operating objectives, to maintain the capability to make opportunistic investments that will provide for growth in future profits and to continue to allocate capital in a way that will maximize stockholder value over time. During the remainder of 2023 the Company may utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD’s existing infrastructure. If there are no better strategic uses for UTMD’s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.

k)Assets and Liabilities

UTMD’s March 31, 2023 Balance Sheet, in the absence of debt, continued to strengthen.

March 31, 2023 total consolidated assets increased $3,896 from December 31, 2022 to $127,770. The increase was due to a $5,860 increase in cash and a $17 increase in net fixed assets (property, plant and equipment), offset by a $667 decrease in current assets other than cash and $1,314 lower net intangible assets.

The increase in cash was due to cash generated from operations coupled with a $781 decrease in non-cash working capital. Current assets as a whole increased $5,193 while current liabilities as a whole increased $114, yielding a $5,079 increase in working capital to $89,038. The decrease in current assets other than cash resulted primarily from a $1,720 decrease in receivables offset by an $1,126 increase in consolidated inventories. Average inventory turns were 2.0 in 1Q 2023 compared to 2.6 for the 2022 year. Accounts receivable were $1,720 lower due to faster collections, with the average age of trade receivables at 27 days from date of invoice at March 31, 2023 compared to 37 days at December 31, 2022. UTMD’s excellent 15.1 current ratio at December 31, 2022 improved to 15.7 at March 31, 2023 because current assets increased 5.8% when current liabilities increased just 1.9%.

The $17 higher net fixed assets at March 31, 2023 compared to December 31, 2022 resulted from $43 in capital expenditures, $155 in depreciation and the impact of the period-to-period foreign currency exchange (FX) rates for assets OUS. FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2023 and the end of 2022 follow:

	3-31-23	12-31-22	Change
GBP	1.237	1.208	+2.4%
EUR	1.087	1.069	+1.7%
AUD	0.670	0.680	(1.5%)
CAD	0.739	0.739	-

At March 31, 2023, net Intangible Assets decreased to 17.5% of total consolidated assets from 19.2% on December 31, 2022 because of the 1Q 2023 $1,588 amortization of identifiable intangibles, offset by a higher FX rate for remaining GBP intangible assets in the UK and aided by the higher period-end total asset denominator.

The $114 increase in current liabilities was a result of a $305 increase in accrued liabilities, primarily for income taxes and customer deposits, offset by a $191 decrease in accounts payable. Long term liabilities increased $19 to $3,678 primarily as a result of an increase in deferred income taxes in the U.S. and Ireland. Long term liabilities declined by a $57 lower deferred tax liability for the Femcare Ltd GBP IIA to $1,456 at March 31, 2023 compared to $9,084 on the date of the 2011 acquisition. Reduction of the deferred tax liability occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare Ltd IIA. UTMD’s total debt ratio (total liabilities/total assets) as of March 31, 2023 was 7.6% compared to 7.8% as of December 31, 2022.

Table of Contents

l)Management's Outlook

Based on the first quarter of 2023 results, UTMD expects to achieve its plan for 2023 as a whole, as described in its 2022 Form SEC 10-K. UTMD’s objectives for 2023 remain to

1)exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations;

2)more effectively market the benefits of the Filshie Clip System in the U.S.;

3)introduce additional products helpful to clinicians through internal new product development;

4)continue to achieve profitable overall financial operating performance and a stable working environment for employees;

5)utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued; and

6)be vigilant for accretive acquisition opportunities which may be brought about by the current challenging economic environment on companies with more limited resources.

m)Accounting Policy Changes

None.

Forward-Looking Information. This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. When used in this document, the words “anticipate,” “believe,” “project,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. The exchange rates were .9198, .9351 and .9013 EUR per USD as of March 31, 2023, December 31, 2022 and March 31, 2021, respectively. Exchange rates were .8085, .8280, and .7603 GBP per USD as of March 31, 2023, December 31, 2022 and March 31, 2022, respectively. Exchange rates were 1.4695, 1.4919 and 1.3338 AUD per USD on March 31, 2023, December 31, 2022 and March 31, 2022, respectively. Exchange rates were 1.3532, 1.3526, and 1.2571 CAD per USD on March 31, 2023, December 31, 2022, and March 31, 2022 respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur, and by optimizing global account structures through liquidity management accounts.

Item 4. Controls and Procedures

The Company’s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2023. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of March 31, 2023, the Company’s disclosure controls and procedures were effective.

There were no changes in the Company’s internal controls over financial reporting that occurred during the quarter ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

UTMD is a party from time to time in litigation incidental to its business. Presently, except for the Filshie clip lawsuits initiated by a single U.S. law firm, there is no litigation or threatened litigation. The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results.

Item 1A. Risk Factors

In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in UTMD’s Annual Report on Form 10-K for the year ended December 31, 2022, which could materially affect its business, financial condition or future results. The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

Legislative or executive order healthcare interference in the United States renders the U.S. medical device marketplace unpredictable. A fully government-run healthcare system would likely eliminate healthcare consumer choice as well as commercial incentives for innovation. Restrictions on “nonessential” medical procedures during a pandemic reduce the demand for certain of UTMD’s medical devices.

Increasing regulatory burdens, including premarketing approval delays, may result in significant loss of revenue, unpredictable costs and loss of management focus on developing and marketing products that improve the quality of healthcare:

Thousands of small focused medical device manufacturers including UTMD that do not have the overhead structure that the few large medical device companies can afford are increasingly burdened with bureaucratic and underqualified regulator demands that are not reasonably related to assuring the safety or effectiveness of the devices that they provide. Premarketing submission administrative burdens, and substantial “user fees” or notified body review fees, represent a significant non-clinical and/or non-scientific barrier to new product introduction, resulting in lack of investment or delays to revenues from new or improved devices. The risks associated with such circumstances relate not only to substantial out-of-pocket costs, including potential litigation in millions of dollars, but also loss of business and a diversion of attention of key employees for an extended period of time from managing their normal responsibilities, particularly in new product development and routine quality assurance activities.

Group Purchasing Organizations (GPOs) in the U.S. add non-productive costs, weaken the Company’s marketing and sales efforts and cause lower revenues by restricting access:

GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD’s, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Otherwise, their business model based on “kickbacks” would be a violation of law. Despite rhetoric otherwise, these bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily driven by collection of their administrative fees.

The Company’s business strategy may not be successful in the future:

As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable and overly cumbersome regulatory environment, the Company’s views of the future and product/ market strategy may not yield financial results consistent with the past.

As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage:

An aging population is placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD’s clinical advantages more difficult.

Table of Contents

A product liability lawsuit could result in significant legal expenses and a large award against the Company:

UTMD’s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. In any lawsuit where an individual plaintiff suffered permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists.

The Company’s reliance on third party distributors in some markets may result in less predictable revenues:

UTMD’s distributors have varying expertise in marketing and selling specialty medical devices. They also sell other devices that may result in less focus on the Company’s products. In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, a distributor of UTMD’s products may eventually become a competitor with a cheaper but lower quality version of UTMD’s devices.

The loss of one or more key employees could negatively affect UTMD performance:

In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. The Company’s benefits programs are key to recruiting and retaining talented employees. An increase in UTMD’s employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.

Fluctuations in foreign currencies relative to the USD can result in significant differences in period-to-period financial results:

Since a significant portion of UTMD’s sales are invoiced in foreign currencies and consolidated financial results are reported in USD terms, a stronger USD can have negative revenue effects. Conversely, a weaker USD would increase foreign subsidiary operating costs in USD terms. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. For the portion invoiced in a foreign currency, not only USD-denominated sales are reduced, but also gross profits may be reduced because finished distributed devices and/or U.S. made raw materials and components are likely being purchased in fixed USD.

Trade restrictions and /or tariffs resulting from changing government trade policies have the potential to disrupt UTMD’s supply chain.

Lack of predictability of a major OEM customer currently representing over 20% of UTMD’s sales.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

UTMD did not purchase any of its own securities during 1Q 2023 and in 2022 it purchased 30,105 of its shares in the open market for $2,495 including commissions and fees ($82.88/ share.)

Item 6. Exhibits

Exhibit #	Title of Document

31.1	Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1	Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101	The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders’ Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UTAH MEDICAL PRODUCTS, INC.

REGISTRANT

Date: 5/5/23 By: /s/ Kevin L. Cornwell

Kevin L. Cornwell

CEO

Date: 5/5/23 By: /s/ Brian L. Koopman

Brian L. Koopman

Principal Financial Officer

EX-31.1 2 utmd_ex31z1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CEO

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin L. Cornwell, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2023

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

EX-31.2 3 utmd_ex31z2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brian L. Koopman, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2023

/s/ Brian L. Koopman

Brian L. Koopman

Principal Financial Officer

EX-32.1 4 utmd_ex32z1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

May 5, 2023

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 utmd_ex32z2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Brian L. Koopman

Brian L. Koopman

Principal Financial Officer

May 5, 2023

EX-101.CAL 6 utmd-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 utmd-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 utmd-20230331_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Cash paid during the period for income taxes Total adjustments Total adjustments Accounts receivable and other receivables Accounts receivable and other receivables Adjustments to reconcile net income to net cash provided by operating activities Statement [Line Items] Other comprehensive income (loss) Common Stock, Shares, Outstanding Other long term liabilities Current assets Amendment Description CooperSurgical Inc Represents the CooperSurgical Inc, during the indicated time period. Product and Service [Axis] Geographical [Axis] Work-in-process Schedule Of Revenues By Product Category Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period. Proceeds from issuance of common stock - options Accrued expenses {1} Accrued expenses Inventories {1} Inventories Statement Cost of goods sold Total current assets Total current assets Security Exchange Name Entity Registrant Name OutsideUsMember Represents the OutsideUsMember, during the indicated time period. Prepaid expenses and other current assets Prepaid expenses and other current assets Provision for losses on accounts receivable Amortization {1} Amortization Common stock received and retired upon exercise of stock options Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period. Comprehensive Income Diluted shares Shares outstanding (diluted) Document Fiscal Year Focus Entity Address, Address Line One Cash paid during the period for interest Earnings per share, basic Earnings per common share (basic) Operating income Operating income Gross profit Gross profit Deferred tax liability - Femcare IIA Other intangible assets Document Fiscal Period Focus Document Transition Report Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System Represents the Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period. Neonatal Represents the Neonatal, during the indicated time period. Obstetrics Represents the Obstetrics, during the indicated time period. Raw materials Policies Payment of dividends Payment of dividends Stock-based compensation expense CASH FLOWS FROM OPERATING ACTIVITIES UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Common stock dividends Common stock dividends Common stock issued upon exercise of employee stock options Equity Components [Axis] Total liabilities Total liabilities LIABILITIES AND STOCKHOLDERS' EQUITY UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical Blood Pressure Monitoring and Accessories Represents the Blood Pressure Monitoring and Accessories, during the indicated time period. Operating Lease, Right-of-Use Asset, Amortization Expense Retained Earnings Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares Goodwill Amendment Flag Entity Tax Identification Number Common stock purchased and retired Stock option compensation expense Other intangible assets - accumulated amortization Other intangible assets - accumulated amortization Property and equipment, net Local Phone Number Entity Small Business Entity Current Reporting Status Details Dilutive effect of stock options Warranty Reserve Net cash provided by operating activities Net cash provided by operating activities Foreign currency translation adjustment Foreign currency translation net of taxes of $0 in all periods Earnings per share, diluted Earnings per common share (diluted) Entity Incorporation, State or Country Code Entity Shell Company Stock-Based Compensation Cash at beginning of period Cash at beginning of period Cash at end of period Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Selling, general and administrative Entity Interactive Data Current Trading Symbol Distribution Rights Acquisition Represents the Distribution Rights Acquisition, during the indicated time period. Finished goods Property and equipment Property and equipment Tax benefit attributable to exercise of stock options Equity Balance, shares Equity Balance, shares Equity Balance, shares Other income Operating expense Common Stock, Shares Authorized Other intangible assets, net Other intangible assets, net Document Type Schedule of Earnings Per Share, Basic and Diluted Revenue Recognition Inventories {2} Inventories Net cash provided by/(used in) financing activities Net cash provided by/(used in) financing activities Depreciation Sales, net Total current liabilities Total current liabilities Inventories Total Cash & Investments Entity Address, State or Province Voluntary filer Document Period End Date Entity Central Index Key DomesticUsMember Represents the DomesticUsMember, during the indicated time period. Allocated Share-based Compensation Expense Basis of Presentation Effect of exchange rate changes on cash CASH FLOWS FROM FINANCING ACTIVITIES Deferred income taxes {1} Deferred income taxes Common stock received and retired upon exercise of stock options, shares Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period. Equity Component UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Research & development Ex Transition Period Current Fiscal Year End Date Distribution Rights Acquisition [Axis] Represents the description of Distribution Rights Acquisition, during the indicated time period. Gynecology/Electrosurgery/Urology Represents the Gynecology/Electrosurgery/Urology, during the indicated time period. Standard and Extended Product Warranty Accrual Tables/Schedules Notes Additional Paid-in Capital Provision for income taxes Common Stock, Shares, Issued Total stockholders' equity Total stockholders' equity Equity Balance, value Equity Balance, value Additional paid-in capital Total assets Total assets Entity Address, City or Town Public Float Finite-Lived Intangible Assets Acquired Product and Service Subsequent Events Common stock purchased and retired, shares Common stock purchased and retired, shares Common stock issued upon exercise of employee stock options, shares Weighted average shares, basic Shares outstanding (basic) Income before provision for income taxes Income before provision for income taxes Common Stock, Par or Stated Value Per Share Current liabilities Entity File Number Earnings Per Share CASH FLOWS FROM INVESTING ACTIVITIES Accounts payable {1} Accounts payable Accumulated other comprehensive loss Deferred income taxes Long-term lease liability Entity Address, Postal Zip Code Document Quarterly Report Well-known Seasoned Issuer Geographical Schedule of Inventory, Current New Accounting Pronouncements, Policy New Accounting Pronouncements and Changes in Accounting Principles Net increase in cash and cash equivalents Net increase in cash and cash equivalents Changes in operating assets and liabilities Net income Net income UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical Total liabilities and stockholders' equity Total liabilities and stockholders' equity Accounts payable Other current assets ASSETS City Area Code Entity Common Stock, Shares Outstanding CSI Distribution Agreement Purchase Disclosure Net cash used in investing activities Net cash used in investing activities Common Stock Total comprehensive income Total comprehensive income Total operating expenses Total operating expenses Retained earnings Stockholders' equity Accrued expenses Accounts & other receivables, net Title of 12(b) Security Entity Emerging Growth Company Entity Filer Category EX-101.PRE 9 utmd-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 utmd-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Warranty Reserve link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Revenue Recognition link:presentationLink link:definitionLink link:calculationLink 000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Warranty Reserve (Details) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2023	May 04, 2023
Details
Entity Registrant Name	UTAH MEDICAL PRODUCTS INC
Entity Central Index Key	0000706698
Document Type	10-Q
Document Period End Date	Mar. 31, 2023
Current Fiscal Year End Date	--12-31
Trading Symbol	UTMD
Entity Tax Identification Number	87-0342734
Entity Common Stock, Shares Outstanding		3,628,067
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-12575
Entity Incorporation, State or Country Code	UT
Entity Address, Address Line One	7043 South 300 West
Entity Address, City or Town	Midvale
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84047
City Area Code	801
Local Phone Number	566-1200
Title of 12(b) Security	Common stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1

XML 12 R2.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash & Investments	$ 80,912	$ 75,052
Accounts & other receivables, net	3,818	5,538
Inventories	9,940	8,814
Other current assets	442	515
Total current assets	95,112	89,919
Property and equipment, net	10,241	10,224
Goodwill	13,502	13,354
Other intangible assets	53,443	52,755
Other intangible assets - accumulated amortization	(44,528)	(42,378)
Other intangible assets, net	8,915	10,377
Total assets	127,770	123,874
Current liabilities
Accounts payable	1,028	1,218
Accrued expenses	5,046	4,742
Total current liabilities	6,074	5,960
Deferred tax liability - Femcare IIA	1,456	1,514
Other long term liabilities	1,256	1,256
Long-term lease liability	328	341
Deferred income taxes	638	549
Total liabilities	9,752	9,620
Stockholders' equity
Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares	36	36
Accumulated other comprehensive loss	(11,490)	(12,039)
Additional paid-in capital	322	251
Retained earnings	129,150	126,006
Total stockholders' equity	118,018	114,254
Total liabilities and stockholders' equity	$ 127,770	$ 123,874

XML 13 R3.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares shares in Thousands	Mar. 31, 2023	Dec. 31, 2022
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	50,000	50,000
Common Stock, Shares, Issued	3,628	3,628
Common Stock, Shares, Outstanding	3,628	3,628

XML 14 R4.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME
Sales, net	$ 12,520	$ 12,323
Cost of goods sold	4,677	4,790
Gross profit	7,843	7,533
Operating expense
Selling, general and administrative	3,260	2,888
Research & development	144	123
Total operating expenses	3,404	3,011
Operating income	4,439	4,522
Other income	680	8
Income before provision for income taxes	5,119	4,530
Provision for income taxes	905	996
Net income	$ 4,214	$ 3,534
Earnings per common share (basic)	$ 1.16	$ 0.97
Earnings per common share (diluted)	$ 1.16	$ 0.96
Shares outstanding (basic)	3,628	3,655
Shares outstanding (diluted)	3,636	3,665
Other comprehensive income (loss)
Foreign currency translation net of taxes of $0 in all periods	$ 549	$ (506)
Total comprehensive income	$ 4,763	$ 3,028

XML 15 R5.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	$ 0	$ 0

XML 16 R6.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Comprehensive Income	Retained Earnings	Total
Equity Balance, value at Dec. 31, 2021	$ 37	$ 841	$ (9,054)	$ 115,314	$ 107,138
Equity Balance, shares at Dec. 31, 2021	3,655
Common stock issued upon exercise of employee stock options	$ 0	19	0	0	19
Common stock issued upon exercise of employee stock options, shares	0
Stock option compensation expense	$ 0	43	0	0	43
Foreign currency translation adjustment	0	0	(506)	0	(506)
Common stock dividends	0	0	0	(1,060)	(1,060)
Net income	0	0	0	3,534	3,534
Equity Balance, value at Mar. 31, 2022	$ 37	903	(9,560)	117,788	109,168
Equity Balance, shares at Mar. 31, 2022	3,655
Equity Balance, value at Dec. 31, 2022	$ 36	251	(12,039)	126,006	114,254
Equity Balance, shares at Dec. 31, 2022	3,628
Common stock issued upon exercise of employee stock options	$ 0	21	0	0	21
Common stock issued upon exercise of employee stock options, shares	0
Stock option compensation expense	$ 0	50	0	0	50
Foreign currency translation adjustment	0	0	549	0	549
Common stock dividends	0	0	0	(1,070)	(1,070)
Net income	0	0	0	4,214	4,214
Equity Balance, value at Mar. 31, 2023	$ 36	$ 322	$ (11,491)	$ 129,150	$ 118,018
Equity Balance, shares at Mar. 31, 2023	3,628

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-19

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 33: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 17 R7.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 4,214	$ 3,534
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	155	149
Amortization	1,596	1,646
Provision for losses on accounts receivable	1	8
Operating Lease, Right-of-Use Asset, Amortization Expense	13	14
Deferred income taxes	(3)	(144)
Stock-based compensation expense	50	43
Tax benefit attributable to exercise of stock options	2	0
Changes in operating assets and liabilities
Accounts receivable and other receivables	1,789	(578)
Inventories	(1,084)	(809)
Prepaid expenses and other current assets	25	(109)
Accounts payable	(193)	695
Accrued expenses	350	597
Total adjustments	2,701	1,512
Net cash provided by operating activities	6,915	5,046
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(43)	(237)
Net cash used in investing activities	(43)	(237)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	21	19
Payment of dividends	(1,070)	0
Net cash provided by/(used in) financing activities	(1,049)	19
Effect of exchange rate changes on cash	37	71
Net increase in cash and cash equivalents	5,860	4,899
Cash at beginning of period	75,052	60,974
Cash at end of period	80,912	65,873
Cash paid during the period for income taxes	129	82
Cash paid during the period for interest	$ 0	$ 0

XML 18 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2023
Notes
Basis of Presentation	(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

XML 19 R9.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements and Changes in Accounting Principles

3 Months Ended

Mar. 31, 2023

Notes

New Accounting Pronouncements and Changes in Accounting Principles

(2) Recent Accounting Standards.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2023

Notes

Inventories

(3) Inventories at March 31, 2023 and December 31, 2022 consisted of the following:

		March 31, 2023		December 31, 2022
Finished goods	$	1,935	$	1,896
Work-in-process		1,500		1,193
Raw materials		6,505		5,725
Total	$	9,940	$	8,814

XML 21 R11.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2023
Notes
Stock-Based Compensation	(4) Stock-Based Compensation. At March 31, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended March 31, 2023 and 2022, the Company recognized $50 and $43, respectively, in stock based compensation cost.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Warranty Reserve

3 Months Ended

Mar. 31, 2023

Notes

Warranty Reserve

XML 23 R13.htm IDEA: XBRL DOCUMENT

Revenue Recognition

3 Months Ended

Mar. 31, 2023

Notes

Revenue Recognition

(6) 1Q 2023 global revenues (USD) by product category:

		Domestic		Outside US		Total
Obstetrics	$	806	$	209	$	1,015
Gynecology/Electrosurgery/Urology		2,520		3,073		5,593
Neonatal		1,385		377		1,762
Blood Pressure Monitoring and Accessories		2,474		1,676		4,150
Total	$	7,185	$	5,335	$	12,520

XML 24 R14.htm IDEA: XBRL DOCUMENT

CSI Distribution Agreement Purchase Disclosure	3 Months Ended
CSI Distribution Agreement Purchase Disclosure	Mar. 31, 2023
Notes
CSI Distribution Agreement Purchase Disclosure	(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie® Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represents an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over the 7 month remaining life, as of the end of 1Q 2023, of the prior CSI agreement with Femcare.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Earnings Per Share

3 Months Ended

Mar. 31, 2023

Notes

Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:

(in thousands)	Three months ended
	March 31,
	2023	2022
Numerator
Net income	4,214	3,534

Denominator
Weighted average shares, basic	3,628	3,655
Dilutive effect of stock options	8	10
Diluted shares	3,636	3,665

Earnings per share, basic	$ 1.16	$ 0.97
Earnings per share, diluted	$ 1.16	$ 0.96

XML 26 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2023
Notes
Subsequent Events	(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

XML 27 R17.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)	3 Months Ended
	Mar. 31, 2023
Policies
New Accounting Pronouncements, Policy	The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Inventories: Schedule of Inventory, Current (Tables)

3 Months Ended

Mar. 31, 2023

Tables/Schedules

Schedule of Inventory, Current

		March 31, 2023		December 31, 2022
Finished goods	$	1,935	$	1,896
Work-in-process		1,500		1,193
Raw materials		6,505		5,725
Total	$	9,940	$	8,814

XML 29 R19.htm IDEA: XBRL DOCUMENT

Revenue Recognition: Schedule Of Revenues By Product Category (Tables)

3 Months Ended

Mar. 31, 2023

Tables/Schedules

Schedule Of Revenues By Product Category

		Domestic		Outside US		Total
Obstetrics	$	806	$	209	$	1,015
Gynecology/Electrosurgery/Urology		2,520		3,073		5,593
Neonatal		1,385		377		1,762
Blood Pressure Monitoring and Accessories		2,474		1,676		4,150
Total	$	7,185	$	5,335	$	12,520

XML 30 R20.htm IDEA: XBRL DOCUMENT

Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)

3 Months Ended

Mar. 31, 2023

Tables/Schedules

Schedule of Earnings Per Share, Basic and Diluted

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:

(in thousands)	Three months ended
	March 31,
	2023	2022
Numerator
Net income	4,214	3,534

Denominator
Weighted average shares, basic	3,628	3,655
Dilutive effect of stock options	8	10
Diluted shares	3,636	3,665

Earnings per share, basic	$ 1.16	$ 0.97
Earnings per share, diluted	$ 1.16	$ 0.96

XML 31 R21.htm IDEA: XBRL DOCUMENT

Inventories: Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Details
Finished goods	$ 1,935	$ 1,896
Work-in-process	1,500	1,193
Raw materials	6,505	5,725
Total	$ 9,940	$ 8,814

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Details
Allocated Share-based Compensation Expense	$ 50	$ 43

XML 33 R23.htm IDEA: XBRL DOCUMENT

Warranty Reserve (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Details
Standard and Extended Product Warranty Accrual	$ 0	$ 0

XML 34 R24.htm IDEA: XBRL DOCUMENT

Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Sales, net	$ 12,520	$ 12,323
Obstetrics
Sales, net	1,015
Gynecology/Electrosurgery/Urology
Sales, net	5,593
Neonatal
Sales, net	1,762
Blood Pressure Monitoring and Accessories
Sales, net	4,150
DomesticUsMember
Sales, net	7,185
DomesticUsMember \| Obstetrics
Sales, net	806
DomesticUsMember \| Gynecology/Electrosurgery/Urology
Sales, net	2,520
DomesticUsMember \| Neonatal
Sales, net	1,385
DomesticUsMember \| Blood Pressure Monitoring and Accessories
Sales, net	2,474
OutsideUsMember
Sales, net	5,335
OutsideUsMember \| Obstetrics
Sales, net	209
OutsideUsMember \| Gynecology/Electrosurgery/Urology
Sales, net	3,073
OutsideUsMember \| Neonatal
Sales, net	377
OutsideUsMember \| Blood Pressure Monitoring and Accessories
Sales, net	$ 1,676

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc $ in Thousands		3 Months Ended
	Mar. 31, 2023	Mar. 31, 2019 USD ($)
Finite-Lived Intangible Assets Acquired		$ 21,000
Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System	7

XML 36 R26.htm IDEA: XBRL DOCUMENT

Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Details
Net income	$ 4,214	$ 3,534
Weighted average shares, basic	3,628	3,655
Dilutive effect of stock options	8	10
Diluted shares	3,636	3,665
Earnings per share, basic	$ 1.16	$ 0.97
Earnings per share, diluted	$ 1.16	$ 0.96

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

XML 37 utmd-20230331_htm.xml IDEA: XBRL DOCUMENT 0000706698 2023-01-01 2023-03-31 0000706698 2023-03-31 0000706698 2023-05-04 0000706698 2022-12-31 0000706698 2022-01-01 2022-03-31 0000706698 2021-12-31 0000706698 2022-03-31 0000706698 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000706698 us-gaap:ComprehensiveIncomeMember 2023-01-01 2023-03-31 0000706698 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000706698 us-gaap:CommonStockMember 2022-12-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000706698 us-gaap:ComprehensiveIncomeMember 2022-12-31 0000706698 us-gaap:RetainedEarningsMember 2022-12-31 0000706698 us-gaap:CommonStockMember 2023-03-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000706698 us-gaap:ComprehensiveIncomeMember 2023-03-31 0000706698 us-gaap:RetainedEarningsMember 2023-03-31 0000706698 us-gaap:CommonStockMember 2021-12-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000706698 us-gaap:ComprehensiveIncomeMember 2021-12-31 0000706698 us-gaap:RetainedEarningsMember 2021-12-31 0000706698 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000706698 us-gaap:ComprehensiveIncomeMember 2022-01-01 2022-03-31 0000706698 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000706698 us-gaap:CommonStockMember 2022-03-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000706698 us-gaap:ComprehensiveIncomeMember 2022-03-31 0000706698 us-gaap:RetainedEarningsMember 2022-03-31 0000706698 fil:DomesticUsMember 2023-01-01 2023-03-31 0000706698 fil:OutsideUsMember 2023-01-01 2023-03-31 0000706698 fil:ObstetricsMember 2023-01-01 2023-03-31 0000706698 fil:ObstetricsMember fil:DomesticUsMember 2023-01-01 2023-03-31 0000706698 fil:ObstetricsMember fil:OutsideUsMember 2023-01-01 2023-03-31 0000706698 fil:GynecologyElectrosurgeryUrologyMember 2023-01-01 2023-03-31 0000706698 fil:GynecologyElectrosurgeryUrologyMember fil:DomesticUsMember 2023-01-01 2023-03-31 0000706698 fil:GynecologyElectrosurgeryUrologyMember fil:OutsideUsMember 2023-01-01 2023-03-31 0000706698 fil:NeonatalMember 2023-01-01 2023-03-31 0000706698 fil:NeonatalMember fil:DomesticUsMember 2023-01-01 2023-03-31 0000706698 fil:NeonatalMember fil:OutsideUsMember 2023-01-01 2023-03-31 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember 2023-01-01 2023-03-31 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember fil:DomesticUsMember 2023-01-01 2023-03-31 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember fil:OutsideUsMember 2023-01-01 2023-03-31 0000706698 fil:CoopersurgicalIncMember 2019-01-01 2019-03-31 0000706698 fil:CoopersurgicalIncMember 2023-03-31 2023-03-31 pure iso4217:USD shares iso4217:USD shares 0000706698 --12-31 Yes false 2023 Q1 10-Q true 2023-03-31 false 001-12575 UTAH MEDICAL PRODUCTS INC UT 87-0342734 7043 South 300 West Midvale UT 84047 801 566-1200 Common stock, $0.01 par value UTMD NASDAQ Yes Non-accelerated Filer true false false 3628067

80912000

75052000

3818000

5538000

9940000

8814000

442000

515000

95112000

89919000

10241000

10224000

13502000

13354000

53443000

52755000

44528000

42378000

8915000

10377000

127770000

123874000

1028000

1218000

5046000

4742000

6074000

5960000

1456000

1514000

1256000

328000

341000

638000

549000

9752000

9620000

0.01

50000000

3628000

36000

-11490000

-12039000

322000

251000

129150000

126006000

118018000

114254000

127770000

123874000

12520000

12323000

4677000

4790000

7843000

7533000

3260000

2888000

144000

123000

3404000

3011000

4439000

4522000

680000

8000

5119000

4530000

905000

996000

4214000

3534000

1.16

0.97

1.16

0.96

3628000

3655000

3636000

3665000

549000

-506000

4763000

3028000

4214000

3534000

155000

149000

1596000

1646000

1000

8000

13000

14000

-3000

-144000

50000

43000

2000

-1789000

578000

1084000

809000

-25000

109000

-193000

695000

350000

597000

2701000

1512000

6915000

5046000

43000

237000

-43000

-237000

21000

19000

1070000

-1049000

19000

37000

71000

5860000

4899000

75052000

60974000

80912000

65873000

129000

82000

3628000

36000

251000

-12039000

126006000

114254000

21000

50000

549000

1070000

4214000

3628000

36000

322000

-11491000

129150000

118018000

3655000

37000

841000

-9054000

115314000

107138000

19000

43000

-506000

1060000

3534000

3655000

37000

903000

-9560000

117788000

109168000

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards. The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

(3) Inventories at March 31, 2023 and December 31, 2022 consisted of the following: <table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top"/><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top"> March 31, 2023 </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">December 31, 2022 </td></tr> <tr><td style="background-color:#CCEEFF" valign="top">Finished goods </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top">1,935 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top">1,896 </td></tr> <tr><td valign="top">Work-in-process </td><td valign="top"> </td><td valign="top">1,500 </td><td valign="top"> </td><td valign="top"> </td><td valign="top">1,193 </td></tr> <tr><td style="background-color:#CCEEFF" valign="top">Raw materials </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top">6,505 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top">5,725 </td></tr> <tr><td valign="top">Total </td><td valign="top">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">9,940 </td><td valign="top"> </td><td valign="top">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">8,814 </td></tr> </table>

<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top"/><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top"> March 31, 2023 </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">December 31, 2022 </td></tr> <tr><td style="background-color:#CCEEFF" valign="top">Finished goods </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top">1,935 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top">1,896 </td></tr> <tr><td valign="top">Work-in-process </td><td valign="top"> </td><td valign="top">1,500 </td><td valign="top"> </td><td valign="top"> </td><td valign="top">1,193 </td></tr> <tr><td style="background-color:#CCEEFF" valign="top">Raw materials </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top">6,505 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top">5,725 </td></tr> <tr><td valign="top">Total </td><td valign="top">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">9,940 </td><td valign="top"> </td><td valign="top">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">8,814 </td></tr> </table>

1935000

1896000

1500000

1193000

6505000

5725000

9940000

8814000

(4) Stock-Based Compensation. At March 31, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended March 31, 2023 and 2022, the Company recognized $50 and $43, respectively, in stock based compensation cost.

50000

43000

(5) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.” UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022 or March 31, 2023.

(6) 1Q 2023 global revenues (USD) by product category: <table style="margin:0 auto;border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="top"/><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">Domestic </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">Outside US </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">Total </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top">Obstetrics </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top">806 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF" valign="top">209 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF" valign="top">1,015 </td></tr> <tr style="height:11.5pt"><td valign="top">Gynecology/Electrosurgery/Urology </td><td valign="top"> </td><td valign="top"> </td><td valign="top">2,520 </td><td valign="top"> </td><td valign="top"> </td><td valign="top">3,073 </td><td valign="top"> </td><td valign="top"> </td><td valign="top">5,593 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top">Neonatal </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">1,385 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">377 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">1,762 </td></tr> <tr style="height:11.5pt"><td valign="top">Blood Pressure Monitoring and Accessories </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">2,474 </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">1,676 </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">4,150 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top">Total </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">7,185 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">5,335 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">12,520 </td></tr> </table>

<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="top"/><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">Domestic </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">Outside US </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">Total </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top">Obstetrics </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top">806 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF" valign="top">209 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF" valign="top">1,015 </td></tr> <tr style="height:11.5pt"><td valign="top">Gynecology/Electrosurgery/Urology </td><td valign="top"> </td><td valign="top"> </td><td valign="top">2,520 </td><td valign="top"> </td><td valign="top"> </td><td valign="top">3,073 </td><td valign="top"> </td><td valign="top"> </td><td valign="top">5,593 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top">Neonatal </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">1,385 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">377 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">1,762 </td></tr> <tr style="height:11.5pt"><td valign="top">Blood Pressure Monitoring and Accessories </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">2,474 </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">1,676 </td><td valign="top"> </td><td valign="top"> </td><td style="border-bottom:0.5pt solid #000000" valign="top">4,150 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top">Total </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">7,185 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">5,335 </td><td style="background-color:#CCEEFF" valign="top"> </td><td style="background-color:#CCEEFF" valign="top">$ </td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">12,520 </td></tr> </table>

806000

209000

1015000

2520000

3073000

5593000

1385000

377000

1762000

2474000

1676000

4150000

7185000

5335000

12520000

(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie® Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represents an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over the 7 month remaining life, as of the end of 1Q 2023, of the prior CSI agreement with Femcare.

21000000

(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2023. The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: <table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">(in thousands) </td><td colspan="3" style="padding-right:5.75pt" valign="top">Three months ended </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"> </td><td colspan="3" style="padding-right:5.75pt" valign="top">March 31, </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"/><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2023 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2022 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Numerator </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Net income </td><td style="padding-right:5.75pt" valign="middle">4,214 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="middle">3,534 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Denominator </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Weighted average shares, basic </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">3,628 </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">3,655 </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Dilutive effect of stock options </td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">8 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">10 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Diluted shares </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,636 </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,665 </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Earnings per share, basic </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">$ 1.16 </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">$ 0.97 </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Earnings per share, diluted </td><td style="padding-right:5.75pt" valign="middle">$ 1.16 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="middle">$ 0.96 </td></tr> </table>

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: <table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">(in thousands) </td><td colspan="3" style="padding-right:5.75pt" valign="top">Three months ended </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"> </td><td colspan="3" style="padding-right:5.75pt" valign="top">March 31, </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"/><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2023 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2022 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Numerator </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Net income </td><td style="padding-right:5.75pt" valign="middle">4,214 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="middle">3,534 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Denominator </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Weighted average shares, basic </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">3,628 </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">3,655 </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Dilutive effect of stock options </td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">8 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">10 </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Diluted shares </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,636 </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,665 </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td></tr> <tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top">Earnings per share, basic </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">$ 1.16 </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle">$ 0.97 </td></tr> <tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top">Earnings per share, diluted </td><td style="padding-right:5.75pt" valign="middle">$ 1.16 </td><td style="padding-right:5.75pt" valign="top"> </td><td style="padding-right:5.75pt" valign="middle">$ 0.96 </td></tr> </table>

4214000

3534000

3628000

3655000

8000

10000

3636000

3665000

1.16

0.97

1.16

0.96

(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 39 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 47 126 1 false 11 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Sheet http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical Sheet http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical Statements 3 false false R4.htm 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME Sheet http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME Statements 4 false false R5.htm 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical Sheet http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical Statements 5 false false R6.htm 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Sheet http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Statements 7 false false R8.htm 000080 - Disclosure - Basis of Presentation Sheet http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles Sheet http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples New Accounting Pronouncements and Changes in Accounting Principles Notes 9 false false R10.htm 000100 - Disclosure - Inventories Sheet http://www.utahmed.com/20230331/role/idr_DisclosureInventories Inventories Notes 10 false false R11.htm 000110 - Disclosure - Stock-Based Compensation Sheet http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation Stock-Based Compensation Notes 11 false false R12.htm 000120 - Disclosure - Warranty Reserve Sheet http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve Warranty Reserve Notes 12 false false R13.htm 000130 - Disclosure - Revenue Recognition Sheet http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition Revenue Recognition Notes 13 false false R14.htm 000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure Sheet http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure CSI Distribution Agreement Purchase Disclosure Notes 14 false false R15.htm 000150 - Disclosure - Earnings Per Share Sheet http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare Earnings Per Share Notes 15 false false R16.htm 000160 - Disclosure - Subsequent Events Sheet http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents Subsequent Events Notes 16 false false R17.htm 000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Policies http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples 17 false false R18.htm 000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables Inventories: Schedule of Inventory, Current (Tables) Tables 18 false false R19.htm 000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables Revenue Recognition: Schedule Of Revenues By Product Category (Tables) Tables 19 false false R20.htm 000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables) Tables 20 false false R21.htm 000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails Inventories: Schedule of Inventory, Current (Details) Details http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables 21 false false R22.htm 000220 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation 22 false false R23.htm 000230 - Disclosure - Warranty Reserve (Details) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails Warranty Reserve (Details) Details http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve 23 false false R24.htm 000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails Revenue Recognition: Schedule Of Revenues By Product Category (Details) Details http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables 24 false false R25.htm 000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails CSI Distribution Agreement Purchase Disclosure (Details) Details http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure 25 false false R26.htm 000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) Details http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables 26 false false All Reports Book All Reports utmd-20230331.htm utmd-20230331.xsd utmd-20230331_cal.xml utmd-20230331_def.xml utmd-20230331_lab.xml utmd-20230331_pre.xml utmd_ex31z1.htm utmd_ex31z2.htm utmd_ex32z1.htm utmd_ex32z2.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 43 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "utmd-20230331.htm": { "axisCustom": 1, "axisStandard": 3, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 284, "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 47, "dts": { "calculationLink": { "local": [ "utmd-20230331_cal.xml" ] }, "definitionLink": { "local": [ "utmd-20230331_def.xml" ] }, "inline": { "local": [ "utmd-20230331.htm" ] }, "labelLink": { "local": [ "utmd-20230331_lab.xml" ] }, "presentationLink": { "local": [ "utmd-20230331_pre.xml" ] }, "schema": { "local": [ "utmd-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 176, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 6, "total": 6 }, "keyCustom": 2, "keyStandard": 124, "memberCustom": 7, "memberStandard": 4, "nsprefix": "fil", "nsuri": "http://www.utahmed.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000100 - Disclosure - Inventories", "menuCat": "Notes", "order": "10", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000110 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "11", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000120 - Disclosure - Warranty Reserve", "menuCat": "Notes", "order": "12", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve", "shortName": "Warranty Reserve", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000130 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "13", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure", "menuCat": "Notes", "order": "14", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure", "shortName": "CSI Distribution Agreement Purchase Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000150 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "15", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000160 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "16", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)", "menuCat": "Policies", "order": "17", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies", "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables", "shortName": "Inventories: Schedule of Inventory, Current (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables", "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET", "menuCat": "Statements", "order": "2", "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables", "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)", "menuCat": "Details", "order": "21", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails", "shortName": "Inventories: Schedule of Inventory, Current (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000220 - Disclosure - Stock-Based Compensation (Details)", "menuCat": "Details", "order": "22", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:ProductWarrantyAccrual", "p", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000230 - Disclosure - Warranty Reserve (Details)", "menuCat": "Details", "order": "23", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails", "shortName": "Warranty Reserve (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ProductWarrantyAccrual", "p", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)", "menuCat": "Details", "order": "24", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fil:ScheduleOfRevenuesByProductCategoryTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1_ProductOrService-Obstetrics", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)", "menuCat": "Details", "order": "25", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails", "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)", "menuCat": "Details", "order": "26", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "UsdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical", "menuCat": "Statements", "order": "3", "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E23Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "UsdPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME", "menuCat": "Statements", "order": "4", "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical", "menuCat": "Statements", "order": "5", "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E21_StEqComps-CommonStock", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "6", "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "E21_StEqComps-CommonStock", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW", "menuCat": "Statements", "order": "7", "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000080 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles", "menuCat": "Notes", "order": "9", "role": "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples", "shortName": "New Accounting Pronouncements and Changes in Accounting Principles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20230331.htm", "contextRef": "Y23Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 11, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Voluntary filer" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "fil_BloodPressureMonitoringAndAccessoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.", "label": "Blood Pressure Monitoring and Accessories" } } }, "localname": "BloodPressureMonitoringAndAccessoriesMember", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.", "label": "Common stock received and retired upon exercise of stock options" } } }, "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.", "label": "Common stock received and retired upon exercise of stock options, shares" } } }, "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fil_CoopersurgicalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the CooperSurgical Inc, during the indicated time period.", "label": "CooperSurgical Inc" } } }, "localname": "CoopersurgicalIncMember", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_DistributionRightsAcquisitionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period.", "label": "Distribution Rights Acquisition [Axis]" } } }, "localname": "DistributionRightsAcquisitionAxis", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "stringItemType" }, "fil_DistributionRightsAcquisitionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period.", "label": "Distribution Rights Acquisition" } } }, "localname": "DistributionRightsAcquisitionDomain", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_DomesticUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the DomesticUsMember, during the indicated time period.", "label": "DomesticUsMember" } } }, "localname": "DomesticUsMember", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_GynecologyElectrosurgeryUrologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.", "label": "Gynecology/Electrosurgery/Urology" } } }, "localname": "GynecologyElectrosurgeryUrologyMember", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_NeonatalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Neonatal, during the indicated time period.", "label": "Neonatal" } } }, "localname": "NeonatalMember", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_ObstetricsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Obstetrics, during the indicated time period.", "label": "Obstetrics" } } }, "localname": "ObstetricsMember", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_OutsideUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the OutsideUsMember, during the indicated time period.", "label": "OutsideUsMember" } } }, "localname": "OutsideUsMember", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.", "label": "Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System" } } }, "localname": "RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "decimalItemType" }, "fil_ScheduleOfRevenuesByProductCategoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.", "label": "Schedule Of Revenues By Product Category" } } }, "localname": "ScheduleOfRevenuesByProductCategoryTextBlock", "nsuri": "http://www.utahmed.com/20230331", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" ], "xbrltype": "textBlockItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r133", "r235", "r256", "r257", "r258", "r259", "r260", "r261", "r342", "r352", "r358", "r377", "r392", "r393", "r396", "r403" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r133", "r235", "r256", "r257", "r258", "r259", "r260", "r261", "r342", "r352", "r358", "r377", "r392", "r393", "r396", "r403" ], "lang": { "en-us": { "role": { "label": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r134", "r135", "r277", "r278", "r279", "r327", "r328", "r329", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r343", "r353", "r361", "r396", "r403" ], "lang": { "en-us": { "role": { "label": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r134", "r135", "r277", "r278", "r279", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r343", "r353", "r361", "r396", "r403" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r10", "r357" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r137", "r138" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts & other receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": { "auth_ref": [], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r32" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r178", "r179", "r180", "r275", "r385", "r386", "r387", "r398", "r405" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r48" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.", "label": "Total adjustments", "totalLabel": "Total adjustments" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r174", "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r6", "r22", "r24" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization {1}", "terseLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r55", "r72", "r89", "r121", "r127", "r131", "r139", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r195", "r199", "r215", "r245", "r299", "r357", "r368", "r394", "r395", "r400" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r67", "r75", "r89", "r139", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r195", "r199", "r215", "r357", "r394", "r395", "r400" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r19", "r69", "r344" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash & Investments" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r19", "r46", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r46" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net increase in cash and cash equivalents", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r359", "r360", "r361", "r363", "r364", "r365", "r366", "r385", "r386", "r398", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r31", "r287" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r31", "r287", "r305", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r31", "r247", "r357" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r16", "r77", "r79", "r83", "r241", "r253" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Total comprehensive income", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r42", "r235" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r6", "r53", "r59", "r192", "r193", "r384" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes {1}", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r183", "r184", "r246" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": { "auth_ref": [], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.", "label": "Tax benefit attributable to exercise of stock options" } } }, "localname": "DeferredTaxExpenseFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r26", "r397" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred tax liability - Femcare IIA" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r6", "r25" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r171", "r172", "r175", "r176", "r177", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Common stock dividends", "negatedLabel": "Common stock dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r84", "r99", "r100", "r101", "r102", "r103", "r110", "r112", "r113", "r114", "r115", "r119", "r210", "r211", "r242", "r254", "r348" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings per share, basic", "verboseLabel": "Earnings per common share (basic)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r84", "r99", "r100", "r101", "r102", "r103", "r112", "r113", "r114", "r115", "r119", "r210", "r211", "r242", "r254", "r348" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings per share, diluted", "verboseLabel": "Earnings per common share (diluted)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r109", "r116", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r220" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r64", "r80", "r81", "r82", "r90", "r91", "r92", "r96", "r104", "r106", "r120", "r140", "r143", "r168", "r178", "r179", "r180", "r186", "r187", "r201", "r202", "r203", "r204", "r205", "r207", "r209", "r221", "r222", "r223", "r224", "r225", "r227", "r231", "r262", "r263", "r264", "r275", "r324" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r71", "r149" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Other intangible assets - accumulated amortization", "negatedLabel": "Other intangible assets - accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r51", "r239" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Other intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r70", "r146", "r240", "r351", "r357", "r390", "r391" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r41", "r89", "r121", "r126", "r130", "r132", "r139", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r215", "r350", "r394" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r40", "r57", "r121", "r126", "r130", "r132", "r243", "r251", "r350" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME", "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r58", "r62", "r105", "r106", "r124", "r185", "r191", "r255" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r18", "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r5" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 11.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts payable {1}", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r5" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 8.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Accounts receivable and other receivables", "negatedLabel": "Accounts receivable and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 12.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses {1}", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r5" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 9.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Inventories {1}", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r5" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 10.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Prepaid expenses and other current assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "CSI Distribution Agreement Purchase Disclosure" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r21", "r23" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Other intangible assets, net", "totalLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Cash paid during the period for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventories {2}", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r50", "r346" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r73", "r345", "r357" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r379" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r378" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r11", "r89", "r139", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r196", "r199", "r200", "r215", "r286", "r349", "r368", "r394", "r400", "r401" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r56", "r249", "r357", "r383", "r389", "r399" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total liabilities and stockholders' equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r68", "r89", "r139", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r196", "r199", "r200", "r215", "r357", "r394", "r400", "r401" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Total current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash provided by/(used in) financing activities", "totalLabel": "Net cash provided by/(used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash used in investing activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r46", "r47", "r48" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash provided by operating activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r60", "r61", "r63", "r65", "r93", "r94", "r97", "r98", "r107", "r108", "r141", "r142", "r188", "r189", "r190", "r206", "r208", "r212", "r213", "r214", "r216", "r217", "r218", "r228", "r229", "r232", "r236", "r237", "r238", "r265", "r266", "r267", "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "New Accounting Pronouncements and Changes in Accounting Principles" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r121", "r126", "r130", "r132", "r350" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating income", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r230" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r381" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r29", "r54", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r74", "r357" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r2" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r2", "r3", "r219", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r17" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payment of dividends", "negatedLabel": "Payment of dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r45" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Property and equipment", "negatedLabel": "Property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r4" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock - options" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r27", "r154", "r157", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r150", "r151", "r152", "r153", "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Warranty Reserve" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r66", "r76", "r78", "r86", "r89", "r95", "r105", "r106", "r121", "r126", "r130", "r132", "r139", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r194", "r197", "r198", "r211", "r215", "r243", "r252", "r274", "r307", "r322", "r323", "r350", "r355", "r356", "r367", "r380", "r394" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r244", "r250", "r357" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r85", "r144" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for losses on accounts receivable" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r28", "r182", "r402" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research & development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r33", "r52", "r248", "r265", "r269", "r273", "r288", "r357" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r64", "r90", "r91", "r92", "r96", "r104", "r106", "r140", "r143", "r178", "r179", "r180", "r186", "r187", "r201", "r203", "r204", "r207", "r209", "r262", "r264", "r275", "r405" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r122", "r123", "r125", "r128", "r129", "r133", "r134", "r136", "r169", "r170", "r235" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Sales, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r308", "r341", "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r37", "r38", "r39" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Equity Balance, shares", "periodEndLabel": "Equity Balance, shares", "periodStartLabel": "Equity Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r15", "r64", "r80", "r81", "r82", "r90", "r91", "r92", "r96", "r104", "r106", "r120", "r140", "r143", "r168", "r178", "r179", "r180", "r186", "r187", "r201", "r202", "r203", "r204", "r205", "r207", "r209", "r221", "r222", "r223", "r224", "r225", "r227", "r231", "r262", "r263", "r264", "r275", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r90", "r91", "r92", "r120", "r235", "r272", "r276", "r280", "r281", "r282", "r283", "r284", "r285", "r287", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r302", "r303", "r304", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r362" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails", "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET", "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r90", "r91", "r92", "r120", "r235", "r272", "r276", "r280", "r281", "r282", "r283", "r284", "r285", "r287", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r302", "r303", "r304", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r362" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails", "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r30", "r31", "r52", "r173" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued upon exercise of employee stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r8", "r15", "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued upon exercise of employee stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock option compensation expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r8", "r30", "r31", "r52" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Common stock purchased and retired, shares", "negatedLabel": "Common stock purchased and retired, shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r8", "r30", "r31", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Common stock purchased and retired" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r31", "r34", "r35", "r49", "r289", "r305", "r325", "r326", "r357", "r368", "r383", "r389", "r399", "r405" ], "calculation": { "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Total stockholders' equity", "periodEndLabel": "Equity Balance, value", "periodStartLabel": "Equity Balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tables/Schedules" } } }, "localname": "TableTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive effect of stock options" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r115" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted shares", "verboseLabel": "Shares outstanding (diluted)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r110", "r115" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares, basic", "verboseLabel": "Shares outstanding (basic)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(5)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r369": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r371": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r372": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r373": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r374": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r375": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r376": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 44 0001811884-23-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001811884-23-000013-xbrl.zip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αE45&*7'ZVC$W&&CXNJ$O+OJ3(:E%40.R'?KP6 MB^W([21%(K_P$K#;$.4M>BQ>A()_:*;/4\- [B+$WRKXTU9UM]4W\ZWB(Z9J MYO\A3:';03S[/]=PBB,2& M01VQXCR)]LP!E(<$S0.2TG3^[ ^64E;3:AL6KCN@[<6':XO:W($#O@A).U#Z M#N=I U1ESN^RM[=]L1T8$[0^WW&X-9@RS]$LUQ3:GZ;_VW>]9QN-9HL-"N>- M!>D)MO7-=EVY^@NY^#MEWLYVTPXU<<>]Z>*<]Y4GUV/N[[@%%!Q2] M2C4\V"MV>8[64P37$V<)'4P.2$L=:0=K8"*B6$XPE?U!RH'1\"+:WW&]YG [ MUNO#=F$1W0'K8>5)T3CLMHVK).>#!GO.(\O0D#89[P]$SHY\L0E47\ MWPL:D!XPN!D&MX*F[.V'LDM49CE@Z_9F'AH>JO%YTA'VWF9T .M.P7HPGV5' MK_L0R;9W<,U $ZDJ975E1/J[@_6@I)/E^_(0 M_W>=Y[N'B;POU)#>;RIO:CA^57)FNFA/.3:N4EZWR=J[1/R.TG%7Z)8I)N2J M2K6U&$;^!A)R]R3C-GN;6[FEJ&M'OQXPO!V[N@@9>$#KB5TZUF=K[\/^,L?^@Z&P>3"6WDY:=L\4SDP);[=&EQOTSBU M-_?G YK>,)H.-;CV!%%OQ6R8)SRE5,'I-6KANL6=ZH<:7-EB<"MH>OP?7##21BE*K'&IPI:PW/ O4'%B7EM7@*K\JZR/K M%NRO3+]]>5[ NT[ S1JKV\_/?:%^]7XS=+=% CLM\)5I.%ZKM&X\WH$N,"SD2^32-$\KN,''>/+=38T+,T: M&)H)0\-/&%CD I]=+5(/.#ULX["-PS8VYW>GGM8W.?RQD0TV.M@HY)A"98;9 M)>LL??QIZ-X(_BO?5*LP:@G_.3I=3]M+ M8G=Z)9T7<+0VULF-.SN?4>G5<_ MG>*SY_,+G6@/O-!WN/:CH UAS#/-_*E-W8_S&R#6_W'QBM JX3_!(I'MQS=D MPC6K$ (A(@)H'1M!.K99.3U>0&8W%"&,SM3)4_2*0MPKI7%\78YK:ZJ*OKNTZ/W5VSB^NK MWO6W[F7[KG.)'RX[5SWXZTOWJGUUT845]^[@I^^=J[M>FJL]]BW-UPU0.TY> M0)#1HR]N?U?^F#O&8#ZVVGG0+.,_1&07H:HCPJ=O'.["8NCC]?!+H/'T0H7G MTG 'INWZ#K^#]7\VR;R=T'.&PVUU@D3M^!O'IQRK)^QNQ%D(C435BXVT1\[Z MG%MLXO")YL!SAL6T 1P@G=Q0/PUOQ#P8R+!<6,= %*,"!>\+W)^96BK\P31+ M9[J-JA\&Q)B^SIEFFGCQ_O[[Y?BK^8[3#Q%[Z*%BO-FHHO3F .RX+0?[[HIUV1/#PGT!_($D0!;@1A3Z"<%+,R. $[<;1> L-=)EQZC/ M&RYAQK8 $S"ZA7C%96-B)?X0>>&$6;!,U]6<*1*+ZX^!-(W_ ) UPX'7(U X MS)V'LGR/NB.N*7I1J0^R\O\!4CFL#0@75FW+\*JW !>P$O@W' #$V\$ M:[5L.(0P$-*V 8,/Z'P;0(2Q"_+B 5"2J9_)*H!L:-H_@=O 1YH3F:\VF9AT MVG#XR(%))N\UR/WU..Y:CP TVYEF+?*$)1O46?E1ZB=UM&T<5TY8L! #WEWH M;D8,88&M,LGR #U2E UM$Z .&#][?N>]P8CKOLFOAR$,!,?R2!G=" ITB0D@ M$2"!:;YG!UHRT+*I35Q^%OPAE5:U5/H%!W!B=RZ %:JKV+R2!IN&2E M,56'0Z#VS:.4+5]5RIO<7Y@MD'R"O7#Y^E(*> +]V'#AK+ 'VUZ619?^O$D^ MJY?/O=OHJI#!!*#\BI"D?,U;T(2=1^[.^\G2:H7=JJP;5I4%Z:Q]E XD\WJ2 M*:=",,W6RC:*2[G.AI3QI^W\*( :,'%LO(7D4Q:\'&NXO:YU(S:7U=FNE=;M MB[9K0.X'7M(Y0&IKK6I*F?/>6^UG>+/9FM1^/F3PQW?;QMKUE MC(/JE0T3:"FMZK[(\?>&X32.1&IOWW(3S9\7 MMNNYE-[S67.Y?J--R0JB(*@A=H0A9=4Y&UY^V#2M1=0<9AJOU3Z-/+ M8;^66%7QB:E9+OLY,F X&FF&%OUAQ(BQ=8"4XP[[TNY]3K3PPSBZ,30&XN'CO_^M62Z7 M/K9[%_27^O&$-=2FPCX9YU$8L8*LIQ[]$L.X9BLTW)E;*7#QN3$XPH9A7_:# MA8")K7D ], $<&TK C.TE9,#"?F SX5E7$"/'D!3O?T<\*27["]?X*Z!5TLT,OZ3KS7LS/I[/U3V$!1,R::,I MQJ+L(UP!#Z_:^.BR"4@Z85W]&;QKN&=,'G-T3P<_N.0UFD@WMHS@1)11/(!I MSMQ8$B_T#/XPFT.^S?#WD*F@3YGQX9 +UQ>>)SK'R !'QD0XIY$^8;@^'&^' MX[_L,=#1D*:!U\.YR7,+EVP #KY,3$]##Z]A2R^-X< >CRNE$YAE*KFB/YF8 M!A?>,N\G3#@M#&W?8<=ED -C@/Y(/(A<2BY(K&!NG0&\1:,-VDH(5KD& JD[ M K@HZ&<2GKC GPXRI&/"B9.V;^G9)PZHO MN-A*Z&*C;8\UP\(<'&"\,[@X@E1QB;!I+!(C0.UZQEC&!H/P#P2EPYEI_.#" MC6D/!KY3I"@6X;F7&';#0>%/$7/ =0#W+)1$$<)E:"+1(0X BAAA@?!R#&X! M$-CG0+[0[Y9F3EV#G*TP 3H*,:HCW,7 U(RQ$"CX>+!ZX1GF3S(P(GS S'9@Y1MHCMVK+S%>6W#Y /DM'!O=Y=8:*?AK MS+]24CV[ LM.4%CG1=8"!?T$!(\U/;'Y=!DI/B[#@]B%M"3"ZNB.6PYJOL]O MA89 9=4SC5X ';9^(MF1^H=06AY,NT_\F9;BLF/ RPE&505\&<7[ UQ%5KBO MAX89<5W+7;F?IY(L+N0(VW9?KY&UD))3>]/XY:U,L$V?L#U&[C;8X6[?$CBQ MY@7*O/M>_DTN.03?O/UP@RRF+"S,UWU0-3S@EJE[/%:F!JR1JI'MS.OG)'R( MA7+OGV-<2KPOH/YCK@ ^]*?AC2Y QP3&Z'2>,#P6=+VVZW+XGYY0$!M$X/]( M<7GM]$!U 9V[,*.<_^EY7[E="/CL?1J)ZLV$HMD'"LV*0M\*"4K9E H%EDOK M]I[-H^?O0'=;H;MT*K^J:WDNU[XQ;$1H7Z<61YP\3$\[:%QPT.SWP)WIZ;U# M7V^HEJ7!5/,W\/J'8C<4.<-B'(D2AUE(Z+)2*R>Y89]A"?G#[8%H5A)-FC*U MHI0:2<%>+Z&9E*^3!TIY.:6D$K]32PP#G*>,'5^7K[AM:2L#@-[B563G4>F[ MH?H V5E(3U6I-+./9#R05?[)*E7YVEBW(.S;NK.^3'>R&WW0%GK458:T:2*FA #NZ/;\1+$ M&5@0TSLKJ*UBG49J ]-!3U MW=_>#X2:#:&FJ8'4E,H;+&=QH,X=4&<:^O REV$*)6[G:Y_%*&^S!,'RZOJN M>:^A6SO4T-U]#=W5%>0\S:*L2#QQ6ZJ=VCAA,(_G&'V?6$3[P>$BDS%(L2F* M3!],0S,Y)1Y&\VP 2AP9A8NI.O?%7A$+GLZ&(T;DAK4]OQBF.S(X',)&]2.[ M,(T)ZTU=CX]%%M*%C;7\>CZL;H#Y(Z+ Z$6O>T*E0GG?\;'*)J4]P-V!\F6> MR?7#JC\>-V%U^CQ\VP.10J/.055M@_:^/)QW:0?>4R^Y$+3"9#'7,J;CEF1\%\ MWRG=['K8">@#(+, U2^V\X6/!]CO4!('4H4@BCA>+LN54J7R&LP 1?.%[!V) MF])JO7X1+91,!V"3FV6F,>24F24K*'*+TO1DQHH2? U(A+, ),VT\*1165X) MA6TF=P;]HV[@S&$F;(9LIGG"@MD83,=H/LI,@U7QX!? '!/U:X%F 2\#GY+F M,;%'QZ[K"&-@Z^P%#J<_#H;A3]P9&(*3 MQM/D-4\L&V2 K!(]B#PE?Y5D-C0U;FB ++M '\])WOBDSZ$$&8= W[ M%?GTRU JL\IBV5XIYW?-M#,=":] @O2L5FR(IS<[?9^,\VBY:"Q?,-?:#U:+ MZ@W)J&R6D9CS,L(4:)F63-4)7F^S3 -@2=?3W4 H3/3,##!+NI2L>BO+ZE'! MQI&%/7_SS@;H&W0=W"%XDDK8IF3?_YC&(=JLE\:G_OE5P*D_G?:?]X:]: ^I M9ERE4(8M*V:5>T#MD+E?A0KDBT]XQH:Y&\<>&MXW>[ZP9EKVMJI27EU(:RO< M=OVN7+E$13KE@"I*K;)&3;-\QB)VR%PW%OJ7L\O81F)_F]C;^[GR MR$3^G#>_"&N+(B[@:\F##->WL: (MM,6N[DB6]+UD(PB[O7,@D0&DM5B7;SS M0G%2+Z_;Q'U+F'Z=R'\S*"ZGB.):FFG!:3(>LOJA(R@H@C=GTLSEE?KEN)=& MS@4":(?-X3([Z"\YY+L^RV\9L:D=;W6-.(A\"?+ \R'D=_I=1-$NDPC(2 MRE+T5](LC;-?HO]M$TF:RD,]K\I#2I($*2 #_&[O_I:=D-T6:/(HI3H+3MS\ MWC0_/%,X-]'I_HRIV-6#IU\6 :,6U?SW.YZ^.79PRE?\[6: 2Y++9]==#Y*Z+94XH$\_LN_\N'&W'G M,M$S:;FXG)BY_ZYRQ8>5]4ZL<6-AQ[J%#PG3M[A=,KS!N!$'@8 MS9HU4/?KL$=YV-@EJ&Y/'=%%%P<,,S-]741$.UP\8-G,II[HKJZY]W,7*_7,3#%IR[_OEWS0(^Z2,Q4L"/2 M?.)+2,>P,5T0/#YSRUW?].B1ZPD7H'"%;_!5 :V;5;_D%DQM;G/*>T\;L>]< MIW8<,J/<#7(@D)>=,'C!QS8IOB-;/L';/[A'74BX:1:XBU)$=*@!IO,@PH6Q M18UF>E,VEH/K')/4DWILA=UTOF ['+54^!U09F$_D5L^L1TO3.28C:OC.0 F?<0SW!_RJC6W@MH(CB[6X@GF[ M(]LW=>PT [Q&1]X*[/S?OB7T!HK(E_U7<-\!J#[S@>:+6&V$@H--W:AK$X[G M8#L@C;;G 99I:43)U+K'FK('>!3#3 M7AAK4Y T'B[?L'1J/_3(9>0Z#",^1J<+@807S?3A0\BS /7@1YOE)DI#@_1.#VF&17)^;"1 M1@S!2Y-@ M6+8GTD\^X%#WO4OVJT@INL18:L?]R-KW^%W;QTP6T]!F/^ $%=D="M[]^OD& MW_V=W:!L8#T0),#X'SZR"QKZHHW#7 "CT@U 6#@*$@8<@4J].ANJ0Q1Y*HMB#=O+I M%,:)#19]KEPM5D1D,CYU_8@E-?C/[4.^*Y),HJW]!/CE^8BG7!RK?YP@8J@] MC3B%(K- ) "5A7:HN3)=P3U[Y59>E'OP1B)< K(2(Q3@@@6JX#.IWL_&(LE$ MK2T&(*6TY/(^+7DP0K5D>8&:W1B',22X!U?Y5_0ZR2B. E]:Q> M8=!X\8M"M67B"[)_!'UXDPP=PL#QUNP;L5JFC:(ZJV0JK1!U8;5Z(9!?,OPV MR/BY%24Y 0/BR @(S_H=GS5"'/]W^XJ1JT.5=M[O[=N3K9M17@[;\O[#=I>J M5?+1BE[CL<$Z/,&.HU^>,A=M1"=G.= Q7H+(>CEN'-FKM:L;7O2SHI+Y.WY( M*?,_;$ MNP1LI5:LK4$4.UUBO=C(RZTLF2@ZG^]".A"\ DONT2U>4@E^W+S"HK3 M"W*(WKS(G:R6?F%PU^(.!L=X\B%;U DG'S5%3QQ?W_=.Q O^A)4KO^ X&%T! M !J[27>X(-#AW@VJ%+K:&"OM.1Q@RP9!Q A_$OX\=OSEGR<,Q!\7T29B(1B@ M8EB/MC'@NIQ284:1%_$#JHAE#.NT,.G)"\>D[]6/8FT*@Z7+T<+U-W\ILB . M!SZ(J!>+U%"*\<2=15Z)KF!N Q1Q1"46Q2[@B2__C&QC-KD.*NY(>^14OGXEZTR<0T!G1[7L 78!BA(V-0 U+"J)>YRWLZ@2YYN\/O*HOK M93>IW08DO&;-NXI(>-F:+W(9DO#U\TT.-*TYXT.QC!WI<[>J2HZ\FL&JCEO% MRO8]B)W[VUT=.K58:C1W-[E:KJY.S>E8KV9 M/QY3*C;*VW$MIDUX-<&&-B:\-.CKHKT&?66&L'6$0F:3-U.=/&VBJ*\BBBW? MC>\BI?@+82E^_B N4K/+UL)E1M[Q-)?5BJU?,-M"]P=XKQ$Y!;&;8'_*/I3A MJA->T&2W@.1K[=QE.[P.=RE))'Y?#2ZJ'C8FC%]$@_M5_/[ZH5HNL>/_JA2K MOYR\MD;_9K8$'TNMNYY)]\ ^]]#:A,'[3IB5,\LO0CABKX\1)L<,X"V"1Q?A M9XF&(61W8'P\,>TIYPP>-+T1=K!@$WAF]DY@AE!$&QG$5]"O 6[!#L?.)F@O M#:"5[(:Y^7ZBL ?Z:2(,K*<$5F65^6+[]IJ+*/ZONU&#C>8!ZC$ CQV3S9U2 ML\C(1S#YT*Q*D'IP'PGOXS &//>!@N3@1;2$SUX,]MDV,3OG8400#E.X@HF7 M>RRZWT^ #BP.X,3UD@EA!">12PN.PK3@,R" L*X!-!P;[DLB/T&0(^;&:"@/#1@?*M4F.RX7FU$0R668AF<\ M4-[+;/@5!$#]@51%+=4H$";(U4CL@Z,%AX#6()KQS/?>H4Q=(N.)!E=([.(" MF^.: V<*.Q+A$C3154BF4 7=8:K W2D!RY7XF>^:))O?)'9/0OIH2GC$F4IT M[ZUB*?)$63PAK$5SV\!)N@9QL0'7>[[1-))3\-T\2$ MM:%OFM-(]R& X/7 L_M!WQ(&[\21(E%-W 39K(*<0_2F"Y*G@QV$5 3H4(.> M.@(G(EU)D:M!R#D&6=R8"]P?MC! OHZB0Q*"S %EU .)M?4Q3(&D0P+D6+9& M.DF@>(5 I9;E89T%RT28PR+^U I(Y2@"%Y\'V%@RF?&G[6 N7NS$PX$6*"3( M+("1N/;" 1(25 5QM"RPIU9"=A41ASO(PIK%Q++CSN>[1;XU]@&IDDL8J!!Q M-^P3!)N-P6F@N1<%SA6"04W@ \JPI:QJ MM/XRW2=YJD6I%]:,IY5CYS-Y+.!%_@02VPN7/4= ";ZI*Q02<3%&7A_:')93 M0&W(T/!(RV63_*(CB*X7!@,DJ%)Q?$0)??DNH]X//%\->;X03E$(PRRE&+T2 M#Y0PQC>)9P1#777%:!BF*;>@1$SBE82^54*7HYB^\ W:]8[.2 R8WX..,6+U MGS70QH#G]T:<>TJ@D(':QRTA"73>]Q3)09'/D'@/T-017:\N\, @3+H6G!@O M4@\#9'FQQ>":81+96?/3QRB_42NJT6<7,L>+K!?IVQ5(R@XP;V]*6$+]N5)L MAH/$4C&C>=)8F,72-2=(F*8#D#"?V&;,-Q.#V)QC)NY?$>_$&W%QC10B.HC8 MM$LV"4,*?)&OAG+'J5VAY-]:WT FOC!QU)NS\/6NHC)C"< %M=@0E:.V[W7? M67)J2F%UE4)%+6S7&32_CUIZ^]BJ@RB3?1R<1ALXC2J-'*ZJD@M7UDM"6H[K MH-^\,]=2U%!%'>E"#>HUNID9\L^HBCH):'5;V(Z%2 Z?;9 MT/OU*35+:L[9$%[(%PDB]"?EN!IAXU"-(%S?BUIPYZ:2+ M3V'WORNB0IJF1 JNH74!5_A_N28?0V_(@["4HUF?)H1%B2F8;CA\@"Y'LGF( MPGO&9((% 8-?/)ML%;X+"QO @: 2A4-M(,T<"CH:L+HA(\N=X>ALHCFS:H:G MK@]@HK*&@<_"=N M.(7HI(I"HX?M%3080, 35Q.6GG39\1U9]"^HC!=6 PKB M9.'A[1TR=,A4\2(1Q]D4A* MV"(>K8)!G40+&-\,7H$%$==JB2**8DD6'(/(:BB.7'X,*:Z/K@&,X!\C1< 0 M$E.&"_3NQT\,K(8H"9<1K#D(O^>6ZY-[:[;Z65W'^:46V8UX0*-ZQ+ 7:EN$ M2*8,$RQ1B5#'502SBRV)D(@?@EF8F@-D*#86$O4R2DX@EI7D&:MK'*0*H!\ MT(P[H4%CAS?R MGOQ;),DZRLA$[#G<$'-R-"/.(L,'KB8MQP%[4=[Y;'C! E M.%+@L.,@4(!,[FJKP8ZITM5)S.<2]7A<+,2I1*)0HB$H&1VD202@/!N?$@@9FV1MOHXIJCO*!/C04M5F; M<[HHK68UP0.''@E\$)B:)6J*ZO.#4W5SIIX$R3I"9(N?@SR=>8UCKL8P+H$D M>X0O'%/E8JZ3Y&;4(! /<51\$[1'-A*39KHG2L2M'09*T 1!H$HY7.1UY_O" M"B/[Q+F%!STH01RMJASGPN*Y^(YH %"%"W-?$\PMH:_ $Y5P/4GKE4M3%J8. M Q8L?08/(3/#="ZYPA<1WKI:<_((0BDNH4:L/J,Y!QJV>.HR0CAXH"?H?+=( MGM=$T(H(GXM3H"*)NM(H,Q%.'SK"0[)?8'P!<1LB7D5ZQK$7@6&1"'5]T$VF MF/(%KP&,'7\BXD+@(VH#QL 'R8<,@4\XW8)A?\ O3.,_J*!J$R!DT,XH$-"! M,3SWU>%FJ6&EO!%6PI,RAY)*>0V4U-BQ6D6SH\")E!^"F:RHXK6(ANHZUO7X^9:00+ JFF5"IS JD*7[5B9S;Z_BQ9\^OG&P6K;RM4 M]9LN:^W+2.JFF"&(/:3P7BT>3"/2.MU87J?X-0P56ZVHA/?C6,S58@SPG$H$ MNZ[5FD&D&;*AJKY-$,8X"+I7D25+]BIP*=@B(4(OJ&VO&Z*E M 3!\.[!W!"H$2 6//]B.$5S*:,] +:;^$S.Q9T"A2POVH/%B 'MM6,9&+_[Y M9^1B ;L^H7MP?"?3MU:^*\<-''-6H7L/ZZ#_LMO%[AUR]ZIB? )R=USEN0_W M ;B9#;93+7ZEIVM#"MQZD7BEE(LHF]BRUDA2/J"MFI^,>KFLUB8,()5@NJG% M<5\/TU/6,?D ;@9HL.(.?+YWZ(>MY7CF0=+ I::UJQX#U36XR)L"M5K:54N% MJIH;27O%;4OS@BY\!X:]9%6JTJCGKH/"ELK#[S/6FHW<]<^):6M;D;*?3=O6 MV8W#77+M?K'-( M+;=:>X746KZNZK%(UH+:0J]+/ RP)1PQ%(>QG:*\^RNOMMJ*;ATPK1_=JY;6 M9XX''&^KK=\6<+Q?Q7[1';0OGIF#\^7@?#DX7P[.EX/S);>BO%S*G0W_8!-Z M7O]:HXSMEMLJ'APONY4R%:6TCJ4P&T]$JB6=W.94^J-^CY=Y2KJP>7R/%*K&YB*<[#@ M2H(UX>!R>2O"Z@.C])G<0.G@<#WT*W*?%> )R;.%4E;VB8@6,:E&=U=!X/JL\ M-DS0O$2VKZ!70N\MIIU/' - 9X@*1]Y/FPVU1R!D2CJ<;QRJ&]0* W;OGKVR M-4L\!59"' <)"M8O+GMA-/F(*&50/A'%]44.+Z M@@3S:JD:98O'Y4:Q'.W*$\OKKR@E8*J1;/%C0&TUH5U1]\$2YB:D_4C'BH2% M4*4G6DU2YY^@% OU\UC6-48F[*_:[D);;55N\[F.+5@!-=Q?@L!HLUBWI-7U M&X"UFI/8 B7]P6?@%&.2C?WIK,\9Q@LE[V:QW5*,VL(1EG;:P=>J+=%]!)B8 MX)1+YL-G*^HN^%.,C(,CQ.-$7,8P>R!%JE(UH]PEJ(#':UAUHUR*-=J*H79A MHJ!04H1$AVM%*S E[+@FZ_7 'F:M=**T?"ZW'7) MP6LVZNRX(6=^YM0U:T#']24G-%ZQC$JZS%5T$15@PGYWP*86UH1,JE%-AP\F M#@ZR;INL3\K_>:!7F@UD".HZ0*]4ZMAF;RF?VQCH"VM"N-1W5Y9(*CZ)/%16 M4JQ6V;$:!U<,1BIJ/>H2(GX)C!;6A#!2M]Q1#938,7R>*HNZQASG7-:Q3PEXW1$2VO;ZD%BHQM!U?>@:)&3M>U0[/6$QGB?X; M;X?S5Y)=G0.\ZN9D[CR>PJ4X#,P4F^-QRRD9S=P5H:A5RCD_H-]F-Y#="LCJ M.CD^FIO+[H2!0T)8A%'LS6$PLZ*.8^ MU6-Q&?0,Z9-@65P&+ ?!K*+OF;]8$,XYQ\QT"I\VG;D M),%[KOSV03,L-PAV&P._\,-0"I !/E%7Y_Z6D=>.!N]CI[Z!8'/41.9W$=>% MCE+YU.R!L/U?-(K@8]#2)KHD1W)="NSR/>J/0A$H "5L&V98CUSRYA!<]E0S MJ060".G#OG&T.P.8CAML0\9/A6%B'A^,+,KZC33O&1ON@)NP5(Z]G<0$@1-@ M$9M&LG.CWE3G_)!+G!;"'3&-A.E%F\M(MT301V(!IJMB/BB^*PQ E'1![J.9 MJQ=I3+3$^%"OUA>>#C9/;8LTT[5GT/W0"IY^#AXA2O'G9)0FK5^9=35 _WKB M+&+H /7%H+69)D8'R6Q2I.<#1<8E0TNC X#4]J'"9.\W[!D9\6G'3@0/5(*% M?AJQ$['=WEVI,-WA1DQ7.M<^E\OCO9/J>%6>-<4^BH2WDL MA?//.0OGXM<"@L&AZ5C7%%5ML>-J*1Y0,.^SK)3(9]E*97@AE^5!O5%:=1 I%B?68(9_G\M,>#=X=#K&=2"RR=B-OZ:X\ MIPA?!"%VD/.T$?LN&ZK=A$'B@.YBK/49H;>LU.KE%0%<+;6^@,?5\WR#"]2Q ME'PG- E*4%5I+9]'/- L+9TJL/]]I1:N-$/P%7PH8G]=XIW!E[,6NS? :N$1 ML1 4TA3RE;@*_/58K;46"3=*H\LV'K;W)3CC;-A@2:TUETTG?HXU$]PN[^C> M7;:I:RF=(HSS:;=OV)@* HE84AIAJU+!3?Z(9' M:\$P;^T))-:C 9=0ZIJ:''T% XKQ9JO1,=)K8&@B2&T^?@\#RJT' V\5&FB( MLK\AM51D]B1ZZ)4(1B/,$^F#Q]80RE ])BQG(I0$-6R)1#).%_*F(&KJ6+8^ M#/O.SDV):)0M$(.>IG4XMJVYJ$BETH@&1J*NP9H8<1ORV'! M9H/4[-;$ML?>3VX^!NU,Y08%=VQBQ,YV-9O8.J,GS=**1#W$UA[B:',35 )/.FTD_"%@A M73NOBR,E/Q].A,N(&-]U4$UM9T$UU:0F/GER&D:]]NVHKI73D+:#]WY%=I", MHGD9'@_1-+NH[DHF$/0)7. U:!].X':ZR6VPH!18;"JQP'0'O19W4#3I _+R M< 1K:S0PR(95YSV@M!M8O*AL&<\],.D&?[XO MFO-9^D)>=BK27NO+T+ZCE6W[0 =;@@$RV0\YYJ+F&V&H23NR/.MM?&",K(G[ MN.Q*8S&L,HRLRG$(D%HZQ "]QQB@A\UB@+@G7;B["?%9S'%%WVQ5*:M5,IZK M+:S[(?VFY%Q%*W3D30I 4&J5F LL;J://"UR6I7H5[HAS/[]:4)M$8464:E@ M&FUDC52#J1G[4CKYPHB3Z%"!WUQ[$EX&EZH'4$+R,=48(G\W>O_GXV'4!DXB M/#HQ9S;,5_I%3"G2=^,#1\<)HU5F&;S"S1\M]#+OS Y<+K#F G_BXXFWN\B, M)"H7U#LZ"7QVFH-E&UQV Z#HC=!>=-RYZ>TBFN*F)VL)10@@F=R0DG\2%\&@ M&TDXPEE"\0^X#7(X2N>A[[D>D (5&](-Y GDE?.T'XAOBEZU7!A<\+:XRU'[ MJ3EZ4/X$UR?]@=*M,P8^.%6D Y 915Y4V B6Q #WSL!P>5#@J\^!W$3=DLG$ M- :1VFGA>5O8DRB2)(+A3K;JG[Z48$*LS)<:*)?F6N[ H$#S1SX)I[:N64F1+(4V65\ M$-I*1:E7ZDJY65_V-CQ0KX(&5DO8XW6$KN8&A=67ZHW$\*Z*8#X+Y$J;0F $ MNZ+ ;]@7@BL*;!Z;L<\'FB^*L6C, WP60BH*!Q*<*B J>W'9$]-W!9#Q66)R MOA50L![&;Q,_U0V'8["!/"!N-+;0H_2"V=:B4RT=$!^"P[2-6NMKWXJ1EACF<$2$+9:_VZ1UA//Y/S!G6,!Y8;26#C."Y$1Y9=C9PX/6PY=<[C8OV5+V>?PH,A3 M-.@W.!^7LS!MBM^@_;L&;G@QF%4)8F2#$74 !=6<0N4)"QT36L)X9SL\_K2D MX!B\>A7EDE('%"0.#NBIEB*E,<7933BSS7*Q7MHJ=@AX$\W X.(/JE)JE-CQ M!Y"_K=HI >Y$A&@+Y52CH9;R2*_+=^%$(,# [$K%S MT+58^;FC,V-E2)+-)BJ2XLMXW5F'>Y1B05BCI#' A6LXLBYQ&/<5A!:*"L5R MNB \;#:9)H^"$8E0PX E3U01?>1R@* 67)28YJZ6 ]-V0Z8LAUW"F3$2K%4M M-AH*T^V?%JO_,LM1^:"62L5:)1PN::"%ZE9K3BWNBQ^:K6*SOH?1]<8)V\2> M<A%0ED0: ""(A(_"%+OC(W?IE/ M[5F^8^ A@ Y1G%>CUVAF.DJ_R..-RN //HWP$(_>$26T$2WC,)PUV D. NHG M$Y(Y6Y8F_R T\T63]DXIS!8M$KL"BQA=VEMB@_%9)J[(-2"(2-<+JZ";)_F MOQFP!YT*QP,I7,BPZUONVK#&P)VU1ZSGWQM94BD\8HBEXW9C225Z"8.8@39F MP=4DU0Q,]8K>T&:9VB),.AK6+LIK1F,]9GE^"R'V3#-1)%-(MJBY2#K73]OY M(0B9"$$1UVI,@:O'+1%SZ2(UI52M)]@I(APAW.:'>K,D$V]L 8'G6P:(B)9( M>7]$@X]?::48Y> H-RLT+8QH:4"5U#)B 1UBYL44@#)=$?3>9"J$*16BGAI MU'^KJC3:$D<@\,(2= X+S(S00DRE?JH1']H-L/<)FF*$3O"9/U@*\"\SX>7N<3KMW)MV[Z9=6->LLE?24PPOMOD $.JR1= MV75]N@N7(JX>NJF2\'C>/D;@U=V80JL/E ML!*]?#M+N9BCE+N5-B?75$[MTDL,S03S_0.$,KIFU:G%$YI+E");%LNS.L6P(//W +WB5=.K9G M 4%Y&@+@R@L^U?">1B'+K1$9%V*PE"BBFBYE0L'=RQ$1>:JSRQ:'RI*LU47@BA4L>0( M9=F)H:$T&B5AJP\O=A%SGH:7^6:]%+OUT0$);K6-V$]8<61H/,U63?%Z1>R][=[TF*0#( 5 M@2A]%D+ "THU1<0)7-(G:&$1V?&@!375&$1"T\V@Z'"3RVE5&E&S<<;X'9Y MS!M@O%$NQ<::F6?<*$%9U%6H7(\C)![7%UHZBJPM==#@2Y!I( ^DT:AH1UOZEN:X2"RZ0+X*3RTPB\1@*OZ$\1N( M0K565$-\$B4GCL*,,6J$,AZC5FPDK"BX3LY1QXP8:UA;B,1K$OW.GD/+*%.+ MK5]V[8:EBD? )H-*1?,<Z0-4;(TX4PG1:5040O; M+:$QOX]:&OM0R[21A,(:>[:1"^(K>:L/\O7S36YR(P.XJL5R)3]M=B*K*N4A M8QNM._!DHZ@"5:[).OZK7*S^L@G-I5)ZYOYVV_G2,UR5UFG4E-GD]2VV5G@1 M/8!@W8@>,N5![?O+')RK.(1*Q7ICC73_[:^JF8=5O83FCM5B[9>3;3.AB_8: MM)45LAJ5K;=8V='D+R&(Q1H(6VX$\?(.$O.7684NO-V934Z:A0/KC; %-&0C MU.563;KDB512VTJX%4>RCZ)5*C^H2JW97*SPB3@QA@9=P68&P[EP&GECEQ?- MN9!BT1%[OE!H6 U>V$>CP9Y!:(^X:(LH=]PMO0GP0$>=I7FVL^VD"[+OQ4UD M"9:5GW-I<1K[4"G5$J.!(J\I4?/=K/S^+#!JX+MP*^ 4NX9^B?F()K45MW_. MAS$5V3>,7,.*^DL,0>C:IL[,2KW1C"QG?C]6;"_)H5S1LLG4ED24-UZV"(Q[ M""*$T6H:A%"%@V,^>+[#:,79./+%F7/0""<(-6\7W;_G&*#T2"V633^]@Q,US&38-H&M/4 MR"<;NF$I#\_E0]^$>8;A&J,[AP'GB[72>4&7C#0R'HMO(B _C9PI]P27#",G MY.XUL.)M%&X--"N*QQ>MG_D/82L?0MCV+(0M%8^LN9%'=A;(^\O7'"\2F"%[&0CMS@%-@4RS3!=H%IV81H3UINZ'A]']8A\@J.R$3B /B@H*!9N- D: M(HRX.4%!C\YOD!?&P- H$Q $S<,HS)BB>*0@MDB'0V[:%"*03_A4-X)/++9- MLK @9,L4\6J::4;+WR=6U1Q3$R*W@["X&<1G#TS".BR11-%'3Y7P<"^BB@+E< M@KR^$)/ >T0H;8HO)>]=1]&--XNBFS5+N0&= M=S!EPENVBQ0UT)^W:IOXU#\'C0U+(Q2^@:HJ>E41-Q0]O_OG\=@.*I)8FBD2,$H1KL@!^E$5EF+" MAR3N(T'=&H8-82PLWIM=?RRK/8PQ9J<_C3X9#A9=@CPN:*9XU. LDJ5#[/)/ M9$E4HX>T"-BR;@]\'$J$MU*OJZ X%!QBD+<3V&I8&DK^(D/9Y[\&'HH:\/S7 MW/6,<<(H0C>?_Q9ENJ4'7U*$+!Q?4W-0EX<3[(K()F%0F IX\WEHH[4(M@9 M-*0KAB#1;E(B=_0$4P0;604=K!*ES$,)(;$ IB!&R79YY&J*D$.3YEJ;E@
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end